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Preface
This dissertation is presented as three chapters including research from one published
research article. Chapter I provides background information and rationale for this study, as well
as a description of the three aims that accomplish the goals of the study. Chapters II explains the
research performed in completing the three aims of the study. The data presented in chapter II
and appendices A-E are published in August 2020 in Communications Biology, entitled
“Coordinated Regulation of Rel Expression by MAP3K4, CBP, and HDAC6 Controls
Phenotypic Switching”. Chapter II contains the data supporting the three aims, entitled
“Coordination of Rel Expression by MAP3K4, CBP, and HDAC6 Controls TS cell Phenotype”.
Chapter III provides a summary of the data presented in chapters II and relates these findings to
past and future work in the field.
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Abstract
Noha Shendy. Ph.D. The University of Memphis. August 2020. Epigenetic Regulation of
Rel Expression by MAP3K4, CBP, and HDAC6 Controls Phenotypic Switching. Major
Professor: Amy. N Abell, Ph.D.
Phenotypic switching occurs during normal development, and these processes are reactivated in
several disease states. We have previously demonstrated the critical role of the MAP3K4
regulated chromatin modifiers CBP and HDAC6 in controlling this switching in trophoblast stem
(TS) cells. We hypothesized that genes co-regulated by CBP and HDAC6 represent critical
regulators of phenotypic switching. Bioinformatic analyses identify 183 co-regulated genes of
which 12% are DNA binding proteins. The highest-ranking gene is the NF-kB family member
Rel. Both CBP and HDAC6 bind the regulatory regions of Rel, controlling histone H2BK5 and
H3K27 acetylation on both promoter and predicted enhancer regions. Re-expression of Rel in
mesenchymal-like TS cells induces a mesenchymal to epithelial transition, in part by promoting
expression of CBP/HDAC6 co-regulated genes. Further, REL binds the Hdac6 promoter,
decreasing both expression and nuclear localization of HDAC6. Together, our work defines an
epigenetic program controlling switching between epithelial and mesenchymal phenotypes.
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Chapter I
Introduction
Specific Aims
Cellular phenotypic switching between epithelial and mesenchymal states occurs via two
reversible processes known as epithelial-mesenchymal transition (EMT) and mesenchymalepithelial transition (MET). Both processes are important during embryonic development and
tissue regeneration. The aberrant regulation of these biological processes is related to many
pathological conditions, including cancer metastasis and organ fibrosis. During EMT, epithelial
cells lose cell-cell contacts and acquire invasive mesenchymal properties. Most studies have
focused on examining EMT and the deleterious effect of its reactivation during cancer
metastasis. However, the mechanisms that drive the reversible process MET are poorly
understood. MET is a fundamental process during embryonic morphogenesis where
mesenchymal cells gain-apical basal polarity and assemble into cohesive structures through the
formation of tight junction proteins. Blocking of MET results in the failure of gastrulation and
the subsequent body plan formation. We use trophoblast stem (TS) cells isolated from kinase
inactive MAP3K4 (KI4) mice (TSKI4 cells). These TSKI4 cells display an intermediate EMT
phenotype, including reduced E-cadherin and loss of apical-basal polarity with gain of front-back
polarity and increased invasiveness. Importantly, TSKI4 cells exhibit stemness properties defined
by the maintenance of self-renewal and multipotency. This combination of stemness and EMT
characteristics makes TSKI4 cells a unique model to study the transcriptional networks regulating
EMT and the reversible process MET. Previously, our lab has shown that this intermediate state
of EMT in TSKI4 cells is due to the loss of histone H2BK5 acetylation (H2BK5Ac) at a subset of
gene promoters. This loss of acetylation is due to the reduced MAP3K4 mediated activation of

1

the histone acetyltransferase CBP and a gain of histone deacetylase HDAC6 expression and
activity. Through our bioinformatics analyses of genome wide RNA sequencing and H2BK5Ac
chromatin immunoprecipitation coupled to deep sequencing (ChIP-seq), we identified a subset of
transcription factors (TFs), whose expression is co-regulated by MAP3K4, CBP, HDAC6, and
H2BK5Ac. We predict that these TFs are master regulators of phenotypic switching in TS cells.
We discovered that the highest-ranking TF is the NF-kB family member REL whose expression
is reduced in mesenchymal-like TSKI4 cells relative to epithelial TSWT cells. Here, we investigate
the role of REL in the regulation of cellular phenotypic switching in TS cells. Further, we define
the epigenetic mechanisms by which REL expression is regulated during EMT.
Our hypothesis is that REL expression is controlled epigenetically by HDAC6 and CBP.
Further, this regulation is critical for controlling phenotypic switching. The goal of this project is
to define the role of REL in the regulation of phenotypic switching between epithelial and
mesenchymal phenotypes and to identify the epigenetic mechanisms by which REL expression is
regulated. We have addressed this goal by examining the role of REL in the regulation of cellular
phenotypes in TS cells. Further, we examined the epigenetic regulation of Rel regulatory regions
by CBP and HDAC6. Importantly, we define an epigenetic program that coordinates gene
expression for controlling phenotypic switching between mesenchymal and epithelial states.
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Background and significance
Cellular phenotypic switching in development and disease
Dynamic phenotypic switching between epithelial and mesenchymal states is crucially
important for embryonic morphogenesis and organogenesis to form body patterns1. These
processes include epithelial to mesenchymal transition (EMT) and mesenchymal to epithelial
transition (MET). During EMT, non-motile epithelial cells lose cell-cell contacts and apicalbasal polarity, while acquiring front-rear polarity and invasive properties. Cells undergoing EMT
show distinctive molecular events, including loss of epithelial cell adhesion proteins like Ecadherin and reorganization of the actin cytoskeleton. The repression of Cdh1 expression is
accomplished by upregulating the expression of EMT-inducing transcription factors (TFs)
SNAI2 and ZEB12. These TFs bind to the Cdh1 promoter and repress E-cadherin expression. In
addition to loss of epithelial gene expression, cells gain mesenchymal marker expression like
vimentin and N-cadherin. Importantly, cells undergoing EMT acquire invasiveness through
increased expression of MMP-2 and MMP-9, which is required for basement membrane
degradation.
EMT is further classified according to biological context into physiological EMT or
pathological EMT3. Physiological EMT is associated with embryonic development and
implantation. During early embryonic stages, a subset of epiblast cells undergo EMT to create
the three germ layers in a process known as gastrulation4. After gastrulation, the epithelial cells
of the neuroectoderm undergo EMT to form the migratory neural crest giving rise to several cell
types, including the peripheral nervous system and melanocytes2. Reactivation of EMT in adult
tissues during wound healing and tissue regeneration is another example of physiological EMT.
During tissue repair processes, EMT is induced due to inflammation and ceases once
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inflammation is attenuated2, 4, 5. Pathological EMT is activated during organ fibrosis and cancer
metastasis. Persistent inflammation during tissue repair processes leads to sustained and
uncontrolled EMT, resulting in the transition of epithelia to myofibroblasts and organ fibrosis6.
During cancer metastasis, the epithelial carcinoma cells transition to motile and invasive cells 7, 8.
Some of these cells show metastatic potential where they can digest through the basement
membrane to enter into the vasculature and eventually initiate new tumors at secondary sites7, 8.
This series of events results in the final, life-threatening manifestations of cancer progression.
Importantly, cancer cells may undergo EMTs to differing extents. Some cancer cells will
undergo complete EMT and transition to a fully mesenchymal state. Other cancer cells can
undergo partial EMT and display intermediate phenotypes, retaining some of the epithelial traits
while acquiring new mesenchymal traits. Cancer cells displaying intermediate phenotypes can
undergo rapid switching between phenotypic states, giving advantages to cancer cells during
disease progression2, 9.
The process of EMT is reversible through MET where mesenchymal cells revert to an
epithelial phenotype, demonstrating the enormous plasticity of cells. MET is critical for the
formation of epithelia at different developmental stages, including trophectoderm (TE)
formation, gastrulation, and somitogenesis1, 10. During MET, mesenchymal cells progressively
establish apical-basal polarity and assemble adheren junctions, gap junctions, and tight junctions.
MET requires the downregulation of EMT-inducing TFs expression to restore the adherens
junction protein E-cadherin expression1. The first MET event occurs in the 16-cell stage morula,
where the peripheral cells of the morula progressively flatten, gain apical-basal polarity, and cellcell junctions1. Eventually, the TE layer, the first formed embryonic epithelium, is generated.
Following the formation of the TE, a second MET event occurs at the interface between the inner
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cell mass (ICM) and the blastocoel to generate epithelial primitive endoderm1, 10. MET also
occurs in later stages of development, such as kidney organogenesis and somitogenesis10.
Although the formation of specialized cell types and organs during embryonic development
requires cell plasticity and successive rounds of EMT and MET, maintenance of the epithelial
state is required during postnatal development and in adult tissues1. Protection and maintenance
of epithelial homeostasis are necessary to maintain tissue integrity and organ function1.
Epithelial phenotype protection is accomplished by the downregulation of EMT-inducing TFs
and the expression of TFs that maintain the epithelial state. For example, OVAL1 and OVAL2
TFs protect the epithelial state by activating the expression of epithelial genes and repressing
expression of EMT-inducing TFs11, 12. Loss of expression of MET-inducing TFs results in the
induction of the EMT process and the mesenchymal phenotype in epithelial carcinomas1, 13. As
EMT induction is important during cancer metastasis initiation, the MET process is essential for
the establishment of tumor cells at secondary sites14. The ability of mesenchymal tumor cells to
revert back to the epithelial state is necessary for tumor formation at secondary sites. In the
bladder cancer cell line TSU-Pr1, tumor formation at metastatic sites was associated with the
epithelial phenotype. Further, fibroblast growth factor receptor-2 (FGFR2) knockdown in TSUPr1 cells resulted in the reversal of the epithelial state and failure to form secondary tumors15. In
addition, Dykxhoorn et al. showed that acquisition of epithelial gene expression such as Ecadherin and cytokeratin-18 is essential for mouse breast cancer lines implanted in mammary fat
pads to metastasize to the lung and liver16. Thus, cellular plasticity and the ability to transition
rapidly between epithelial and mesenchymal states is highly advantageous during tumor
progression14. These important roles of EMT/MET processes in development, tissue
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regeneration, and in diseases, including tissue fibrosis and cancer metastasis make these
processes an important field of study.
MAPK Signaling and MAP3K4
Mitogen activated protein kinase signaling (MAPK) controls many cellular processes,
including EMT, survival, proliferation, differentiation, and inflammation in response to a wide
variety of stimuli, including growth factors and stress. The MAPK signaling cascade consists of
three core kinases. The upstream MAPKKK (MAP3K) phosphorylates and activates the
downstream MAPKK (MAP2K). Ultimately MAPK is phosphorylated and activated by the
active MAPKK (Fig. 1)17, 18. In mammalian cells there are twenty-one MAP3Ks, seven
MAP2Ks, and eleven MAPKs. In response to extracellular signals, MAP3Ks are activated by
small G proteins, MAP4Ks, and oxidative stress. There are three main MAPK families:
extracellular signal-regulated kinases (ERKs), c-Jun amino-terminal kinases (JNKs), and stressactivated protein kinases (p38)(Fig. 1)17, 19, 20. The ERK family is divided into two groups:
classical ERKs (ERK1,2) and larger ERKs such as ERK517, 19, 20. The ERK pathway is mainly
activated by growth factor stimulation of MAP2K1 and MAP2K2. Environmental and cellular
stresses activate JNK and p38 pathways, however they can also be stimulated by growth factors.
JNK activation is primarily mediated by MAP2K4 and MAP2K7, whereas p38 can be activated
by MAP2K3 and MAP2K6 (Fig. 1)19.
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Fig. 1 Schematic overview of major MAPK signaling pathways in mammalian cells.
Extracellular stimuli such as growth factors, cytokines, and cellular stresses activate different
MAPKs pathways adapted from Morrison 201217.

During embryonic development, both JNK and p38 pathways are activated by MAP3K4
through activation of MAP2K4/7 and MAP2K3/6, respectively21, 22. Expression of MAP3K4 is
important during embryonic development, and its loss results in significant defects in neural tube
closure, skeletal patterning, implantation, and inner ear hair cell development21-23. MAP3K4
kinase activity is positively and negatively regulated by the interaction of its regulatory domains
with specific proteins. The N-terminus of MAP3K4 contains a kinase autoinhibitory domain and
a growth arrest DNA damage-inducible 45 binding (GADD45) domain (Fig. 2)24. The Cterminus consists of a CDC42 and RAC interactive binding (CRIB)-like domain and a 37-kDa
kinase domain (Fig. 2)24. MAP3K4 kinase activity is autoinhibited by folding of the kinase
7

autoinhibitory domain over the C-terminal kinase domain, preventing interaction with its
substrate25. Interaction of specific proteins with MAP3K4 releases the C-terminal kinase domain,
resulting in dimerization and subsequent activation of MAP3K4 (Fig. 2). Proteins that positively
regulate MAP3K4 activity include TNF Receptor Associated Factor 4 (TRAF4), AXIN1, and
GADD45 a, b, and g24. TRAF4 and MAP3K4 interact through the MAP3K4 kinase domain and
the TRAF domain of TRAF424, 26, 27. Association of TRAF4 with MAP3K4 induces MAP3K4
dimerization and enhances MAP3K4 phosphorylation of MAP2K4/7, resulting in the activation
of JNK26. In addition, AXIN1 is a binding partner for MAP3K4 and positively regulates
MAP3K4 activation of JNK27. GADD45 proteins bind to the N-terminal region of MAP3K4 and
release the autoinhibition of its kinase domain, activating MAP3K425. In contrast, glycogen
synthase kinase-3 beta (GSK3b) negatively regulates MAP3K4 activity. GSK3b blocks
MAP3K4 dimerization by binding to the kinase domain of MAP3K4 and phosphorylating its Nterminus at specific sites24. Together, these studies have defined the regulatory mechanisms of
MAP3K4 signaling pathways.
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Fig. 2 Schematic diagram of MAP3K4 regulatory domains and interacting proteins. MAP3K4
has four domains. The N-terminus contains GADD45 binding domain (BD) and a kinase
autoinhibitory domain (AID). The C-terminus consists of a dimerization domain (DD) and 37kDa kinase domain (KD).
Due to the high expression levels of MAP3K4 in early embryonic stages, several mouse
knockout and knock-in models were created to define MAP3K4 functions during development.
MAP3K4 knockout using targeted deletion of exon3 in C57BL/6 mice results in embryonic
lethality and neural tube defects (NTDs) due to increased apoptosis in neuroepithelial cells22.
In addition, the ENU mutagenesis approach created a premature stop codon at amino acid 382 of
1597 of MAP3K4, resulting in an unstable truncated MAP3K428. Deletion of MAP3K4 using
this approach results in neural closure defects and gonadal sex reversal in XY embryos due to the
loss of Sry expression, demonstrating the critical role for MAP3K4 in sex determination28. One
limitation for knockout models is the potential compensation by other MAP3Ks and the loss of
MAP3K4-specific protein interactions. To avoid these problems, Abell et al. used a knock-in
approach to create a kinase inactive MAP3K4 (KI4) mouse model in C57BL/6 ´ 129Sv
background21. They created a point mutation in MAP3K4 by substituting the active site lysine at
position 1361 with arginine (K1361R) in the kinase domain. Unlike the deletion of MAP3K4,
this approach allowed the dissection of the specific functions that are dependent on MAP3K4
9

kinase activity. Similar to MAP3K4 knockout mice, KI4 mice show NTDs, including spina
bifida and hindbrain exencephaly. However, KI4 mice exhibit additional defects, such as severe
skeletal patterning malformation, infertility and implantation defects21, 29. Also, loss of MAP3K4
activity results in deafness due to the impairment of inner ear hair cell development and
differentiation23. These dramatic phenotypes in MAP3K4 knock-in mice relative to knockout
models suggest that the potential compensation in knockout mice by other MAP3Ks masks some
phenotypes related to MAP3K4. Importantly, developmental defects observed in knockout and
knock-in mice are due to dysregulation of EMT processes, suggesting that MAP3K4 is a critical
regulator of EMT during embryonic development21, 29.
The MAP3K family is composed of twenty-one family members. Within this family
MAP3K1-5 form a subfamily called the STE kinases that have homology to STErile11(STE11)
kinase in yeast30, 31. Several knockout and knock-in mouse models were created to define roles of
MAP3K1-3 during development. MAP3K1 knockout mice exhibit eye open at birth (EOB)
phenotype due to impairment of epithelial cell migration and thus defective eyelid formation32.
Further, MAP3K1 deficient mice have abnormal retinal structure due to aberrant proliferation
and cell death, which result in early onset of retinal degeneration33. Targeted mutation in the
catalytic domain of MAP3K2 results in increased T cell proliferation in response to anti-CD3
monoclonal antibody34. MAP3K3 knockout mice exhibit disruption of blood vessels formation in
the placenta, defects in cardiovascular development, and die at E11.535 . These data demonstrate
the critical role of MAP3K3 for embryonic angiogenesis35 Together, these studies demonstrate
the diverse and crucial roles for MAP3K signaling during development.
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Trophoblast Stem Cells and Phenotypic Switching
In addition to NTDs, embryos homozygous for the K1316R mutation (HOM KI4) display
defective implantation and decidualization29. These early developmental defects ar due to
hyperinvasion and dysregulated EMT/MET processes in trophoblast stem (TS) cells during
differentiation 29. Importantly, these defects result in early embryonic loss of HOM KI4 embryos
TS cells can be isolated from the TE layer of E3.5 pre-implantation embryo36. The TE
layer is critical for embryonic implantation in the uterine wall and contributes to the formation of
the placenta. During implantation, epithelial TS cells in the TE undergo EMT and convert into
invasive trophoblast giant cells that invade the endometrium. In vivo, fibroblast growth factor
(FGF4) is secreted by embryonic stem (ES) cells in the inner cell mass (ICM) and bind to the
FGFR2 receptor on the surface of the TS cells to maintain their stemness features, including selfrenewal and multipotency37. Culture of TS cells indefinitely in vitro requires the presence of
FGF4 and conditioned media produced from mitotically inactivated mouse embryonic fibroblasts
(MEF-CM)36. Upon Removal of FGF4 and MEF-CM, TS cells lose expression of stemness
markers Cdx2, Elf5, Eomes, Esrrb, Sox2, and Tfap2c37-39. In addition, TS cells differentiate into
multiple trophoblast subtypes, including syncytiotrophoblasts, spongiotrophoblasts, and
trophoblast giant cells. These different trophoblast lineages express specific markers such as
Gcm1, Tpbpa, Prl3d1, Prl2c2, SynA, and SynB and contribute to the formation of the functional
placenta37-39.
MAP3K4 activity mediates the activation of p38 and JNK in response to FGF4 in TS
cells29. In HOM KI4 embryos, loss of MAP3K4 activity results in implantation and
decidualization defects due to perturbed EMT29, 40. TS cells isolated from wild-type blastocysts
(TSWT) and cultured in presence of FGF4 form epithelial colonies with apical-basal polarity and
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tight cell to cell adhesions. TS cells isolated from KI4 (TSKI4) conceptuses display an
intermediate state of EMT, exhibiting both epithelial and mesenchymal characteristics41. TSKI4
cells exhibit key characteristics of EMT, including reduced expression of epithelial markers like
E-cadherin with increased expression of EMT-inducing TFs and mesenchymal markers like
vimentin. Importantly, TSKI4 cells show increased motility and invasiveness relative to TSWT
cells29, 41. This work demonstrated the critical role of MAP3K4 in the regulation of EMT in TS
cells. Although TSKI4 cells cultured in FGF4 display EMT, these cells maintain stemness
properties, providing a unique model to study intermediate states of EMT in the context of
stemness41.
Epigenetic Regulation of EMT in TS cells
Epigenetic regulation of gene expression is essential for establishing cell lineage identity.
Epigenetic mechanisms include DNA methylation, histone post-translational modifications, and
RNA mediated processes42. In eukaryotic cells, genomic DNA is wrapped around an octamer
composes of histone proteins (two copies of each histones H2A, H2B, H3, and H4) to form
compacted and highly organized chromatin structures43. Post-translational modifications of the
N-termini of histone tails control chromatin arrangement and accessibility for the transcriptional
machinery42, 44. Histone post-translational modifications include acetylation, methylation,
ubiquitination, phosphorylation, and sumoylation42. The combinations of different epigenetic
modifications control gene expression, controlling lineage identity and specification during
development. The best studied histone modifications are transfer of methyl groups (methylation)
and the transfer of acetyl groups (acetylation) to lysine residues 42, 44.
Histone methylation occurs on lysine or arginine residues and is mediated by lysine
methyltransferases (KMT) or arginine methyltransferases (PRMT), respectively45. Histone
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methylation recruits specific regulatory proteins to the chromatin resulting in the activation or
repression of transcription depending on the site of the methylated residue46. Lysine can be
monomethylated (me1), dimethylated (me2), or trimethylated (me3), providing another layer of
regulation46. Genes that are marked with histone H3 trimethylation at lysine 4 (H3K4me3) at
their promoter regions are actively transcribed46. In contrast, H3K27me3 is associated with
repressed promoter regions. Active or primed distal regulatory regions of DNA (enhancers) are
enriched for the H3K4me1 mark42. However, some modifications have the ability to activate or
repress transcription depending on the modified region. For example, H3K36 and H3K9
methylation results in repression of transcription at promoter region. However, at coding regions
H3K36 and H3K9 methylation results in activation of gene transcription42.
Addition of acetyl groups to lysine residues at the N-termini of histone tails results in
neutralization of histone positive charge and loosens the condensation of chromatin. Histone
acetylation is a hallmark of active chromatin (euchromatin) and is catalyzed by histone
acetyltransferases (HATs)47, 48. In contrast, histone deacetylases (HDACs) remove acetyl groups
from lysine residues42, 48, 49. Deacetylation of histones results in condensation of chromatin and
formation of heterochromatin, which is associated with transcriptional repression. Decondensation of chromatin by histone acetylation is not sufficient to induce transcription47, 48.
Recruitment of chromatin modifiers by acetylated histones is required to establish full chromatin
accessibility. For example, H2BK5Ac recruits bromodomain binding proteins SWI/SNF such as
SMARCA4 and SMARCA2, which weaken DNA-histone interactions and shift nucleosomes to
facilitate TF binding47, 50. Acetylation of H2BK5 on promoter regions is an indicator of gene
expression and is associated with regulation of EMT in stem cells and cancer cells41, 51. One of
the most conserved histone acetylation modifications is H4K16Ac, which is associated with open
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chromatin. In Drosophila, replacement of H4K16 with arginine results in lethality only in males
due to the loss of H3K16Ac induced X chromosomal dosage compensation52. Importantly, loss
of H3K16Ac is linked to many cancers52. Another important histone modification is H3K27Ac.
This modification is enriched on the active enhancers, cis-regulatory DNA sequences that
promote transcription at their target promoters over large distances and independently of
orientation53. During development, activation of lineage-specific enhancers in pluripotent
embryonic stem cells results in formation of developmentally restricted lineages54, 55. Active
enhancers are marked with both H3K27Ac and H3K4me1, while poised enhancers are
characterized by the presence of H3K4me1 and H3K27me3. Inhibition of the histone
acetyltransferases CBP and p300 using GNE-049 results in decreased of H3K27Ac at enhancer
regions and loss of enhancer activity56, 57. These data suggest that enhancer activity requires
CBP/p300 dependent H3K27Ac56, 57.
Embryonic development requires dynamic epigenetic programs that regulate gene
expression during different cellular fate decisions. In early developmental stages, preimplantation embryos undergo the first cell decision resulting in the formation of the
trophectoderm (TE) layer and the inner cell mass (ICM). Embryonic stem (ES) cells in the ICM
form the embryo and trophoblast stem (TS) cells in the TE layer give rise to different trophoblast
subtypes, which contribute to the placenta 58. Cell lineage segregation of ES cells and TS cells is
accomplished by epigenetic regulation of DNA methylation and histone modification37, 59. DNA
methylation is associated with silenced gene expression. Several studies showed differential
global DNA methylation levels result in embryonic and extraembryonic lineage segregation and
specification, where DNA of TS cells is hypomethylated relative to ES cells60. DNA
hypomethylation is essential for trophoblast differentiation and establishment of implantation.
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Inhibition of DNA methylation in ES results in their trans-differentiation into trophoblast giant
cells61. Importantly, recent genome-wide analysis of ES and TS cells showed that the differences
in DNA methylation levels are found within intergenic regions and centromeric
heterochromatin62. In contrast, DNA methylation levels at promoter regions showed no
differences between ES and TS cells62. These data suggest that DNA methylation may not be
involved in cell lineage establishment of ES and TS cells8, 63.
Besides DNA methylation, histone modifications are important during lineage
specification. TS cell chromatin shows reduced levels of the repressive mark H3K27me3 relative
to ES cells8, 63. However, H3K27me3 levels are increased in post-implantation extraembryonic
tissues8, 63. These data suggest gene repression mechanisms in TS cells are independent of
H3K27me3. Abell et al. showed that TS cells are dependent on histone acetylation to regulate
expression of genes required to maintain their epithelial phenotype under stemness conditions41.
Upon FGF4 withdrawal, histone acetylation of all four core histones is reduced, which is
associated with differentiation and induction of EMT41. These data suggest that histone
acetylation is essential to maintain cell identity in TS cells. It has been shown that the TS cell
epithelial phenotype is maintained by CBP mediated acetylation of H2AK5 and H2BK5 on the
promoter of epithelial genes41. CBP activity is promoted by MAP3K4 activity in epithelial TSWT
cells41. Loss of MAP3K4 activity in TSKI4 cells results in reduced CBP mediated acetylation and
induces EMT41. These data are consistent with reduced H2BK5Ac and induced mesenchymal
phenotypes in TSWT cells with CBP knockdown41. In addition, MAP3K4 protects the epithelial
genes from the histone deacetylase HDAC6 mediated deacetylation by promoting the ubiquitination
and degradation of HDAC6 in epithelial TSWT cells64. Importantly, inactivation of MAP3K4 results
in elevated expression and activity of HDAC664. HDAC6 promotes differentiation and EMT by
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deacetylating H2BK5 on the promoters of epithelial genes such as tight junction proteins Cldn6,
Ocln, Tjp1, Tjp2, and Tjp364. Further, knockdown of HDAC6 in mesenchymal like TSKI4 cells
restored H2BK5Ac and thus the epithelial phenotype. Together, these studies show that the TS cell
EMT program is controlled by an epigenetic program of histone acetylation. This epigenetic program
is regulated by the MAP3K4 dependent chromatin modifiers HDAC6 and CBP.
We predicted that MAP3K4, CBP, HDAC6 and H2BK5Ac co-regulated genes are critical
regulators of EMT in TS cells. We identified a small network of 183 genes whose expression is coregulated by the chromatin modifiers CBP and HDAC6 and are dependent on H2BK5Ac. Twelve
percent of the 183 co-regulated genes are TFs. We predicted that these TFs maybe master regulators
of EMT. Expression and promoter histone acetylation of the Rel gene shows the most significant
changes. Rel expression is reduced in mesenchymal-like TSKI4 cells relative to epithelial TSWT cells.
We predict that Rel expression may be important for phenotypic switching between epithelial and
mesenchymal phenotypes. Further, we hypothesize that CBP and HDAC6 coordinate Rel transcript
levels epigenetically by directly binding to Rel regulatory regions.

REL is a member of the nuclear factor-kB (NF-kB) family of TFs. The critical roles of
NF-kB family members during embryonic development have been demonstrated by the
embryonic lethality of knockout mouse models of different NF-kB members65-68. However,
dissection of the role and function of individual NF-kB member has been a challenge due to the
functional redundancy of the five family members. Our work provides insight into the role of the
NF-kB family member, REL during embryonic development in TS cells69-72.

The NF-kB Transcription Factor Family
The NF-kB family is a group of TFs that is evolutionarily and structurally conserved
across a wide range of species from Drosophila melanogaster to Homo Sapiens73. This group of
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TFs is important for diverse biological processes, including development, immune response,
inflammation, wound healing, cell proliferation, and cell death73. NF-kB dysregulation is
correlated with many diseases, including cancer, autoimmune diseases, and chronic
inflammation69, 70. The mammalian NF-kB family consists of five members: REL, RELA,
RELB, NF-kB1, and NF-kB2. In contrast to REL, RELA, and RELB, which are synthesized as
mature proteins, NF-kB1 and NF-kB2 are synthesized as the large precursor forms p105 and
p100, respectively (Fig. 3)74. The precursor forms p105 and p100 are processed through
proteasomal cleavage into the active forms p50 and p52, respectively. All NF-kB members form
homodimers or heterodimers through shared N-terminal Rel homology domains (RHD). This
domain is responsible for DNA binding, IkB binding, nuclear translocation, and homo- or
heterodimerization (Fig. 3)74. The transactivation domain (TAD) is only present in RELA,
RELB, and REL. This domain mediates transcriptional activity of NF-kB dimers (Fig. 3)74. NFkB1, and NF-kB2 and their processed forms p50 and p52 lack the TAD. Thus, their homodimers
fail to activate transcription, and instead act as repressors of gene expression (Fig. 3)74.
NF-kB dimers exist in inactive pre-synthesized forms, which allows rapid activation of
NF-kB in response to infection and cellular stresses72. In unstimulated cells, NF-kB dimers are
sequestered in the cytoplasm by binding to NF-kB inhibitory proteins (IkBs). Ankyrin (ANK)
repeats in IkBs mediate the binding of IkBs to the RHD of NF-kB proteins, masking their
nuclear localization signal72. Similar to IkBs, unprocessed p105 and p100 contain ANK repeats
in their C-termini, so they can function as IkBs and block NF-kB dimers from translocation to
the nucleus (Fig. 4)72. Upon stimulation, the activated IkB kinase (IKK) complex phosphorylates
IkBs, resulting in proteasomal degradation of IkBs. Then, the released NF-kB dimers translocate
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to nucleus and bind promoter and enhancer regions containing kB sites with the consensus
sequence GGGRNNYYCC ( N = any base, R = purine, and Y = pyrimidine)70, 74, 75.

Fig. 3 Diagram depicts the protein structure of NF-kB family members. All NF-kB proteins
share a conserved Rel homology domain (RHD) at their N-termini. Only RELA, RELB, and
REL have C-terminal transactivation domains (TAD). Unprocessed p100 and p105 are
characterized by the presence of Ankyrin (ANK) repeats at their C-termini. The number of
amino acids in each member is indicated on the right. Adapted from Hayden and Ghosh (2008)74.
Signaling pathways to NF-kB
There are two main pathways for NF-kB activation, canonical (classical) and alternative
(non-canonical) pathways75. The canonical pathway activates the classical IKK complex, which
consists of two catalytically active subunits (IKKa and IKKb) and the regulatory subunit NEMO
(IKKg)74, 75(Fig. 4). This pathway is activated in response to a wide range of stimuli, including
pro-inflammatory cytokines tumor necrosis factor a (TNFa) and Interleukin-1b (IL-1b), and the
bacterial wall component lipopolysaccharides (LPS)74, 75. Upon stimulation, the IKK complex is
activated by phosphorylation of the IKKb subunit. The active IKK complex phosphorylates IkB
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members (IkBa, IkBb, and IkBe) on serine residues74, 75. This process targets IkB proteins to
ubiquitination of on specific lysine residues. Ubiquitinated IkB is directed to the 26S proteasome
for complete degradation. Released NF-kB proteins can translocate to the nucleus (Fig. 4)75. The
activation of this pathway is self-limiting through autoregulatory negative feedback loops. For
example, NF-kB dimers promote expression of their inhibitory proteins IkBa by direct binding
and activation of promoters. The newly synthesized IkBs proteins translocate to the nucleus,
remove NF-kB dimers from DNA, and export them back to the cytoplasm70, 74, 75.
The alternative pathway is stimulated by specific TNF superfamily cytokines, including
lymphotoxin B (LTb) , CD40, and BAFF. This pathway is critical for the development and
maintenance of secondary lymphoid organs and maturation of B cells72. The alternative pathway
is only dependent on IKKa. Phosphorylation and activation of IKKa are mediated by NF-kBinducing kinase (NIK)72. Active IKKa phosphorylates p100 associated with RELB.
Phosphorylation of the carboxyl terminus of p100 induces polyubiquitination and partial
proteasomal degradation to generate p52 (Fig. 4)72. Active p52-RELB dimers translocate to the
nucleus to exert their function72. p52-RELB target genes are important for adaptive immunity.
The alternative pathway response is slow and persistent consistent with a role in development of
lymphoid organs and B cell76. In contrast, the canonical pathway response is rapid and transient
consistent with its role in immune response and inflammation76.
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Fig. 4 Canonical and alternative signaling pathways. (a) The induction of the canonical pathway
by binding of LPS, TNFa, and IL-1 to their receptors results in activation of IKK complex
through phosphorylation of IKKa. Active IKK complex phosphorylates IkBa and induces its
subsequent proteasomal degradation, releasing active NF-kB dimers to enter the nucleus. (b) The
alternative pathway is activated by different cytokines such as CD40, BAFF, and LTb and
involves phosphorylation of IKKa by NIK. Phosphorylated IKKa leads to subsequent p100
processing and release of p52:RELB dimers to the nucleus. Adapted from Espin-Palazon
(2016)69.
NF-kB family roles in embryonic development
Although the roles of NF-kB in immune responses and inflammation are well
established, their roles during embryonic development have been difficult to define due to the
complexity of the NF-kB pathway69, 71. Drosophila is used as a model to study NF-kB roles
during embryogenesis, because of the conservation and simplicity of its NF-kB pathways69. In
Drosophila, NF-kB pathways have fewer genes, which prevent compensatory effects observed
with greater numbers of NF-kB proteins in more complex mammalian genomes69, 77. NF-kB
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pathway homologs in Drosophila include Dorsal and Dif (Rel, RelA, and RelB homolog), Relish
(Nf-kb2 homolog), Cactus (IkB homolog), and Toll (IL-1R homolog)69. The importance of the
NF-kB pathway in early embryonic stages is demonstrated by the involvement of several NF-kB
members in the regulation of dorsal-ventral (DV) patterning in Drosophila69, 77. During DV
patterning, the ventral and dorsal axis are established through the activation and translocation of
Dorsal to the nuclei of ventral cells, which promotes the expression of specific ventral genes. In
dorsal cells, IkB protein (Cactus) binds and retains Dorsal inactive in the cytoplasm78. Studies
showed that embryos lacking Cactus expression are completely ventralized69. In contrast, loss of
dorsal expression results in completely dorsalized embryos69. In vertebrates with simpler
genomes such as Xenopus laevis and Danio rerio, NF-kB has been shown to be essential for DV
patterning and other developmental programs, including neural tube formation, muscle
development, and hematopoiesis68, 69.
Studies of knockout mice have pointed to the essential roles of NF-kB during embryonic
development in mammals, which is highlighted by the embryonic lethality of single knockouts of
RelA, Ikkβ, or NEMO69. However, these studies pose a challenge in dissecting roles and
functions of individual NF-kB member due to the complexity and function redundancy of NFkB family members65, 68, 69, 71, 79. For example, mice with a single deletion of IKKa or IKKb have
partial NF-kB activity and do not show NTDs68, 71. However, IKKa and IKKb double deficient
mice have neural tube closure defects and NF-kB activity is completely lost68. These findings
suggest that both IKKa and IKKb can partially compensate for the absence of each other and
mask other possible roles for these kinases during embryonic development68. Another example,
RelA knockout is embryonic lethal at E15 due to fetal liver apoptosis mediated by
TNFa. However, RelA/Rel double knockout results in earlier embryonic lethality at E13.566. This
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earlier onset of liver degeneration indicates that single RelA deletion is partially compensated by
Rel66, 80. One limitation of using double knockout models has been the difficulty of
distinguishing between the effect of compensation and the cumulative effect of double
deletions73. In our TSKI4 cell model system, all NF-kB members are expressed, but they do not
compensate for the loss of Rel. This lack of compensation provides us with a unique system to
dissect the specific roles of Rel in TS cells.
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Specific Aim1: Define the role of REL in promoting the mesenchymal to epithelial transition in
mesenchymal like TSKI4 cells.
Our preliminary data show that Rel was the only NF-kB family member with altered
transcript expression in mesenchymal-like TSKI4 cells. Rel expression is reduced in
mesenchymal-like TSKI4 cells relative to epithelial TSWT cells at both transcript and protein
levels. Based on these data, we predicted that Rel may have a critical role in controlling
phenotypic switching in TS cells. To define the role of Rel in controlling the cellular phenotype,
mesenchymal-like TSKI4 cells were stably transduced with the lentiviruses to express REL either
constitutively or under a Tet-inducible promoter. Both constitutive and inducible re-expression of
REL increase the expression of epithelial markers, decrease mesenchymal marker expression,
and importantly reduce cell invasiveness in TSKI4 cells. These data suggest that REL expression
induces phenotypic switching from mesenchymal to epithelial phenotypes. In addition, we
wanted to examine if the effects of REL on cellular phenotype were selective for REL, or if these
effects could be mediated by other NF-kB family members. Lentiviral expression of another NFkB family member, RELB induces the transition of TSKI4 cells to a fully mesenchymal state.
Together, these data suggest the selectivity of NF-kB family members in the regulation of
cellular phenotype in TS cells.

Specific Aim 2: Define the epigenetic mechanisms that regulate Rel expression in TS cells.
Based on our bioinformatics analyses of RNA-seq and anti-H2BK5Ac ChIP-seq data, we
discovered that Rel expression is co-regulated by MAP3K4, CBP, and HDAC6, and is
H2BK5Ac dependent. Our hypothesis is that CBP and HDAC6 directly bind to Rel promoter and
enhancer regions promoting or repressing Rel expression, respectively. To confirm our
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hypothesis, we examined the binding of CBP and HDAC6 on the Rel promoter and predicted
enhancer regions using ChIP experiments. We detected CBP enrichment on the Rel promoter and
predicted enhancer regions in TSWT cells. However, enrichment of CBP on the Rel promoter was
decreased in TSKI4 cells relative to TSWT cells with no change on the enhancer regions. These
data suggest that CBP promotes expression of Rel in epithelial TSWT cells by binding to Rel
regulatory regions. Importantly, inactivation of MAP3K4 activity in mesenchymal-like TSKI4
cells reduces binding of CBP to the Rel promoter and decreases the expression of Rel. Further,
we discovered that HDAC6 binds directly to Rel regulatory regions, deacetylating H2BK5 and
H3K27. These data suggest that loss of Rel expression in MAP3K4 inactive TSKI4 cells is due to
increased expression and activity of HDAC6 on Rel regulatory regions. Together these data,
define an epigenetic mechanism for coordination of Rel expression in TS cells.

Specific Aim 3: Define the mechanism by which REL induces MET in mesenchymal like TSKI4
cells.
Our data show that loss of MAP3K4 mediated CBP activity and gain of HDAC6
expression and activity results in reduced REL expression in TSKI4 cells. Importantly, REL reexpression in mesenchymal-like TSKI4 cells was sufficient to induce MET. To define the
mechanism by which REL induces MET, we analyzed microarray data from TSKI4 cells
constitutively re-expressing REL (TSKI4R). Microarray analysis revealed that the expression of
71% of MAP3K4, CBP, and HDAC6 co-regulated TFs is restored in TSKI4R cells relative to
TSKI4 cells. These data suggest that one potential mechanism for REL induction of MET is by
the regulation of other MAP3K4, CBP, and HDAC6 co-regulated TFs. Further, we found that
REL re-expression in TSKI4R cells reduces HDAC6 expression and nuclear localization. To
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determine if REL regulates HDAC6 expression directly, we examined the enrichment of REL on
the Hdac6 promoter. REL was enriched on the Hdac6 promoter in TSWT cells. Together these
data suggest that REL promotes the epithelial phenotype by repressing HDAC6 expression and
nuclear translocation.
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Chapter II
Coordination of Rel Expression by MAP3K4, CBP, and HDAC6
Controls TS cell Phenotype
Introduction
Phenotypic switching plays a critical role during normal development, and pathways
controlling this switching are reactivated in many disease states1. Epithelial to mesenchymal
transition (EMT) is a biological program controlling the cellular phenotype1, 5. During EMT,
cells lose epithelial features, including cell-cell adhesion and epithelial markers and gain the
expression of EMT-inducing transcription factors (TFs) and mesenchymal markers. Cells that
undergo EMT acquire motility and/or invasiveness. EMT is reversible through a mesenchymal to
epithelial transition (MET), demonstrating the enormous plasticity of cells. However, the
mechanisms promoting the switch from mesenchymal to epithelial states are more poorly
understood compared to those that drive EMT1.
We have previously defined epigenetic mechanisms that control phenotypic states in
trophoblast stem (TS) cells41, 64. We isolated these multipotent TS cells from wild-type (TSWT)
blastocysts and from embryos created from intercrosses of mice heterozygous for a point
mutation in MAP3K4 that inactivates its kinase activity29. Loss of MAP3K4 activity in TS cells
(TSKI4 cells) induces an intermediate EMT state in which cells display both epithelial and
mesenchymal properties41. TSKI4 cells maintain stemness defined by self-renewal, multipotency,
and chimera competence29, 41. Using these cells that maintain stemness in the context of EMT,
we showed that MAP3K4 induces histone lysine acetyltransferase CREBBP (CBP) activity and
inhibits histone deacetylase6 (HDAC6) expression and activity41, 64. TSKI4 cells lacking
MAP3K4 activity have reduced CBP activity and increased HDAC6 expression and activity.
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Previously, we showed that CBP and HDAC6 control the acetylation of Histone H2B at lysine 5
(H2BK5Ac) on gene promoters that we predicted are important for epithelial state maintenance41,
64

. CBP acetylates promoters and promotes the epithelial state, whereas HDAC6 deacetylates

promoters resulting in EMT41, 64, 81. We predicted that CBP and HDAC6 co-regulated genes are
critical regulators of phenotypic switching. However, the genes controlled and thus inducing the
process are mostly undefined.
Herein, we performed bioinformatics analyses of RNAseq and anti-H2BK5Ac ChIP-seq
data to identify genes co-regulated by MAP3K4, CBP, and HDAC6. Approximately 25% of coregulated genes also had reduced H2BK5Ac on their promoters in TSKI4 cells relative to TSWT
cells, suggesting that CBP and HDAC6 may directly regulate the expression of these genes by
acetylating and deacetylating their promoters. Within these co-regulated genes, 12% were DNA
binding proteins that could be drivers of the epithelial maintenance program. The highestranking DNA binding protein was the NF-kB family member Rel. We show that Rel transcript
expression is reduced in mesenchymal-like TSKI4 cells deficient in MAP3K4 kinase activity, and
re-expression of Rel in TSKI4 cells induces MET. The epigenetic regulation of Rel expression
involves direct interaction of CBP and HDAC6 with the regulatory regions of Rel. In epithelial
TSWT cells, Rel expression is promoted by CBP binding to both promoter and predicted enhancer
regions. In mesenchymal-like TSKI4 cells, HDAC6 is bound to the promoter and predicted
enhancer regions of Rel, and HDAC6 promotes the deacetylation of histones H2BK5 and
H3K27. Finally, we show that Rel induces a switch to an epithelial phenotype by promoting the
expression of most of the CBP/HDAC6 co-regulated DNA binding proteins. Further, REL
directly binds the Hdac6 promoter, represses Hdac6 expression, and reduces nuclear localization.
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In summary, we define an epigenetically controlled, cellular program regulating the expression
of Rel to drive switching between mesenchymal and epithelial states in TS cells.
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Methods
Cell lines and culture conditions
TSWT cells (male) and TSKI4 cells (female) were isolated as previously described from crosses of
mice heterozygous for a targeted mutation in MAP3K4 that substitutes the active site lysine at
position 1361 with arginine, inactivating MAP3K4 kinase activity26, 29. TS cells were cultured in
the absence of feeders in 30% TS media, which includes RPMI 1640, 20% heat inactivated fetal
bovine serum (FBS), 1% penicillin and streptomycin (PS), 1% L-glutamine, 1% sodium
pyruvate, and 100 µM β-mercaptoethanol) and 70% TS media conditioned by mitotically
inactivated mouse embryonic fibroblasts (MEF-CM)29. To maintain stemness, TS cell medium
was supplemented with FGF4 (37.5 ng/ml) and heparin (1 µg/ml). To induce differentiation, TS
cells were cultured in the absence of MEF-CM, FGF4, and heparin29. HEK293T cells (fetal
female) were a kind gift from Dr. Gary Johnson (UNC, Chapel Hill) and cultured using
Dulbecco’s modified essential medium supplemented with 10% FBS and 1% PS81. All cell lines
were cultured in a humidified atmosphere at 37C containing 7% CO2 (mouse) or 5% CO2
(human)81.
Plasmids
Using the Gateway Cloning system, FLAG-tagged human REL and RELB expressing lentiviral
constructs were generated by cloning pDONR223-REL (clone# 53942 BC117191, Vidal human
ORFeome (Version 5.1)) and pENTR223-RELB plasmid (clone# HsCD00515954, DNASU
plasmid repository) respectively into a lentiviral FLAG tagged destination vector82. A
doxycycline inducible lentiviral construct expressing human REL (Tet-on inducible REL) was
also created using Gateway Cloning. The REL coding sequence was cloned from pDONR223REL into the doxycycline (Dox) inducible system pCW57.1 vector (Addgene). Control TS cells
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were created using lentiviral pLKO plasmid. Crebbp shRNA knockdown cells were created
using lentiviral TRCN0000012723 and TRCN0000012727 plasmids (Dharmacon). The Firefly
3X NF-kB luciferase reporter gene was kindly provided by Dr. A.S. Baldwin (UNC Chapel
Hill)83.
Lentiviral production and infection
Lentivirus was produced in HEK293T cells as previously described81. Briefly, HEK293T cells
were cultured until reaching 50-60% confluency. Using calcium phosphate, cells were cotransfected with packaging plasmid (psPAX2) and envelope plasmid (pMD2.G)(Addgene), and
either pLKO, FLAG tagged expression constructs, shRNAs, or Tet-on inducible constructs. Viral
supernatants were harvested after 48 and 72 hours of transfection using ultracentrifugation. Viral
pellets were resuspended in 100 µl of TS media with growth factors. TS cells were infected with
the lentiviruses as previously described41. Stably transduced cells were selected using 1 µg/ml
puromycin. To express REL transiently, TSKI4 cells transduced with Dox inducible REL
lentivirus (TSKI4R) were treated with 1 µM 5-aza-2'-deoxycytidine (Aza) for 48 hours and 2
µg/ml Dox for 96 hours. Then, RNA and proteins were harvested for further analysis. To
establish the stable expression of Dox inducible REL in TSKI4R cells, cells were treated with 1
µM Aza for 48 hours and 2 µg/ml Dox for 96 hours. Then, cells were cultured and treated
continuously every other day in the presence of Dox alone.
RNA sequencing
Libraries were prepared by the High Throughput Genomic Sequencing Facility (HTSF) at the
University of North Carolina at Chapel Hill according to the manufacturer’s instructions
(Illumina). The Ensembl mouse reference genome GRCm38 build 84 was used to align all reads
generated by Illumina HiSeq84. The reference genome index was created using Bowtie2 and the
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RNA-seq reads for each sample were aligned to the reference genome using TopHat285, 86. The
aligned reads for each sample were then independently processed using GFOLD and the
reference gene annotation to obtain normalized reads per kilobase million (RPKM) values for
each gene87. All three aforementioned packages Bowtie2, TopHat2, and GFOLD, were run with
default parameters. Zero RPKM values were converted to “epsilon”, a small number equaling
2.2204e-16 to avoid division-by-zero errors during fold change calculations.
RNA sequencing analyses using DAVID
Functional enrichment analysis for the 183 MAP3K4, CBP, HDAC6, and H2BK5Ac dependent
genes was performed using DAVID88, 89. Only 92 of 183 genes were annotated. Enrichment of
categories in the Molecular Function Gene Ontology (GO) terms were examined using a
threshold EASE score of 0.1.
Microarray data
Total cellular RNA isolated using the RNeasy Plus Minikit (Qiagen) was labeled and hybridized
to Affymetrix GeneChip Mouse Gene 2.0 ST Arrays at the Feinstone Center at the University of
Memphis according to manufacturer’s instructions (Affymetrix). Functional enrichment analysis
was performed on genes whose expression is upregulated in TSKI4 cells re-expressing REL
(TSKI4R) relative to TSKI4 cells using DAVID88, 89. Genes with a (log2(fold change) ³ 2.0 and
with an FDR < 0.05 were examined. Enrichment of categories in the Cellular Component GO
terms were examined using a threshold EASE score of 0.1.
Cell lysates, immunoprecipitation, and Western blotting analysis
TS cell whole-cell, nuclear, cytoplasmic, and histone lysates were prepared as previously
described29, 41. Briefly, whole cell lysates were generated after disrupting the cells using buffer A
(20 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA and 1% Triton) with protease
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inhibitors (1 mM PMSF and 100 KIU/ml aprotinin) and phosphatase inhibitors (2 mM sodium
vanadate and 20 mM sodium fluoride)41. Nuclear proteins were extracted in RIPA buffer (buffer
A, 0.1% sodium dodecyl sulfate and 0.1% sodium deoxycholate) with protease and phosphatase
inhibitors as described above. Cytoplasmic proteins were extracted in 0.5% Triton in 1X
phosphate buffered saline (PBS) with protease and phosphatase inhibitors as described above41.
Then, histones were extracted from the remaining nuclear pellets in 0.2 N HCl overnight with
shaking at 4C. All antibodies used for Western blotting analysis are listed in Appendix C.
Real-time quantitative PCR
TS cell total cellular RNA was isolated using an RNeasy Plus Minikit (QIAGEN), and cDNA
was prepared from 3 µg of total RNA using the High-Capacity cDNA reverse transcription kit
(ThermoFisher Scientific) as previously described81. Gene expression was measured using iTaq
Universal SYBR Green Supermix (Bio-Rad) and the Bio-Rad CFX96 Touch. Gene expression
levels were calculated using 2−ΔΔCT method and normalized to Actb, Rps11, or Gapdh as
specified in the figure legends. Primers used are specified in Appendix D.
NF-kB luciferase reporter assay
TS cells were transfected using the Neon Transfection System (Life Technologies). Briefly, 1
x105 cells were resuspended in 10µl of R buffer containing 500 ng of the Firefly 3X NF-kB
luciferase and 50 ng of Renilla luciferase constructs (Promega). Electroporation was carried out
at 1400V with 10 ms pulse width for 3 pulses. Cells were cultured in antibiotic free media.
Twenty-four-hours post transfection, Firefly luciferase activity was determined by a dual
luciferase assay system according to the manufacturer’s instructions (Promega) and normalized
to Renilla activity to account for differences in transfection efficiency. Luciferase activity was
measured with a Synergy H1MD plate reader (BioTek).
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Invasion assays and isolation of invasive trophoblasts
Matrigel invasion assays were carried out as previously described41, 81. Briefly, TS cells were
seeded on growth factor reduced Matrigel coated 8 µm pore transwell inserts. Invasion assays
were terminated after 48 hours. Non-invading cells were removed from the top of transwells by
swabbing and washing with 1X PBS. TINV cell RNA was isolated from the bottom of tranwells
by lysing cells directly in RNAeasy RLT lysis buffer (Qiagen). To measure cell invasiveness,
TINV cells at the bottom of transwells were fixed in 3% paraformaldehyde for 10 min and nuclei
were stained with DAPI (2 µg/ml) for 30 min. Using an EVOS epifluorescence microscope, five
10X fields were captured per transwell. The cell number in each image was counted manually.
Graphs were plotted using Prism7 (version 7.0, GraphPad Prism software).
Transwell solute flux assay
Barrier function was measured as previously described64. Briefly, cells were seeded in a 24 well
plate on 0.4 µm pore size PET membrane Transwells (Corning Life Sciences). After three days,
cells were confluent and 70 kDa rhodamine B isothiocynate-Dextran dye (1 mg/ml) was added to
the top of each transwell. Fluorescence of dye in the lower chamber was measured using a
Synergy H1MD plate reader (BioTek).
Immunofluorescence staining and confocal microscopy
Immunofluorescence staining was performed as previously described64, 81. Briefly, cells were
plated on acid washed glass coverslips in six-well culture plates for two or three days. Cells were
fixed with 3% paraformaldehyde in 1X PBS for 10 min, permeabilized using 0.1% Triton for 3
min, and blocked using 10% goat serum for 1 hour at room temperature (RT). Cells were
incubated with anti-E-cadherin primary antibody overnight at 4C. After washing three times with
1X PBS, coverslips were incubated with DAPI (0.1 µg/ml), Dy-Alexa 488 (1:500) (Thermo
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Fisher Scientific) for one hour at RT. Coverslips were washed for 30 min and mounted on slides
using media containing 90% glycerol and 10% 1 M Tris pH 7.5. Images were captured using a
Nikon A1 laser scanning confocal microscope and a 40X Plan Fluor 1.3 NA oil objective.
Images were captured with lasers at 408 and 488 nm. Individual z-stacks were obtained. Twodimensional images were displayed using Extended Depth of Focus (EDF- Nikon NIS Elements)
at all wavelengths.
Live cell imaging
Live cell imaging was performed as previously described using a Lionheart FX automated live
cell imager (BioTek)81. In brief, cells were cultured for 48 hours in 6-well tissue culture dishes
before imaging. Using BioTek Gen5 software, we defined the beacons for each well. Then, the 3
X 3 images were captured through the 20X objective every 5 min for 28 hours. Images were
stitched and movies were created using BioTek Gen5 software.
In silico Hdac6 promoter analysis for REL specific binding sites
The Hdac6 promoter region was predicted based on the position of CpG islands and H3K4me3
marks using the UCSC genome browser. The promoter region was defined as -1 bp to -1000 bp
upstream of the transcription start site. Four potential REL binding sites were predicted on the
Hdac6 promoter region using MATCHTM tool (public version 1.0)90. These sites were found -61,
-90, -194, and -436 bp upstream of the Hdac6 transcription start site. Sites at -61, and –90 bp
were predicted to be binding sites for all NF-kB members, whereas sites at -194, and -436 bp
were predicted to be specific REL binding sites. Based on the close proximity of the sites located
at -194 bp and -436 bp, we designed primers to detect this region using anti-REL ChIP-PCR.
Forward primer: CTT CAG GCG CAA ACC ACA C.
Reverse primer: TCC GGG TCT CGA ACT AGG G
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Chromatin immunoprecipitation coupled to PCR
ChIP was performed using a Simple ChIP Plus Enzymatic Chromatin IP Kit (9005S, Cell
Signaling) according to the manufacturer’s instruction. Briefly, TS cells were crosslinked in 1%
paraformaldehyde for 10 min, and the reaction was stopped by adding glycine. Cells were lysed
in lysis buffer A, nuclei were pelleted, and treated with micrococcal nuclease (0.5 µl per 4×106
cells) for 20 min at 37C. Digestion was terminated using 0.05 M EDTA. Then, samples were
sonicated for 20 sec at 40% and then 30 sec at 60% to disrupt the nuclear membranes. The
supernatant was transferred to new tubes after centrifugation. Samples were treated with RNase
and proteinase K to digest RNA and proteins in the samples. DNA-protein crosslinks were
reversed at 65C for 90 min. Then, DNA was purified using MinElute columns (Qiagen). DNA
was analyzed using agarose gels and quantified using a Qubit 3.0 Fluorometer (Thermo Fisher
Scientific). Immunoprecipitation was performed using 10 µg of DNA and 1 µg of antibodies
overnight at 4C with rotation, followed by incubation with Protein G magnetic beads for 2 hours
at 4C. Beads were washed, and chromatin was eluted. DNA-protein crosslinks were reversed,
and DNA fragments were purified. The purified DNA was analyzed using real time qPCR
analysis and ChIP primers listed in Appendix E.
Statistical methods
qPCR data were analyzed using two-tailed unpaired Student’s t test corrected for multiple
comparisons using the Bio-Rad CFX Maestro software (version 3.0). Statistical analyses of other
data were performed using Prism7 (version 7.0, GraphPad software). Prism7 was used to
perform a two-tailed unpaired Student’s t test or ANOVA with Bonferroni’s Multiple
Comparison test. Information about statistical methods for all experiments including statistical
tests used, value of n, and what n represents is defined in each figure legend. A *p value < 0.05,
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**p value < 0.01, ***p value < 0.001, and ****p value < 0.0001 were all considered statistically
significant.
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Results
Identification of genes whose expression is MAP3K4, CBP, HDAC6, and H2BK5Ac dependent
Based on our previous work defining the critical roles of MAP3K4, CBP, HDAC6, and
H2BK5Ac in regulation of cellular phenotype, we performed bioinformatics analyses to identify
genes whose expression levels are coordinately regulated by MAP3K4, CBP, HDAC6, and
H2BK5Ac41, 64. Using RNA-seq, we compared transcript levels in control wild-type (TSWT) cells
and TS cells expressing kinase-inactive MAP3K4 (TSKI4 cells). To identify CBP dependent
genes, we measured transcript levels in TSWT cells expressing lentiviral shRNA for Crebbp
(TSWTCBPsh). Previously, we showed that HDAC6 expression and activity are increased in TSKI4
cells64. To identify HDAC6 dependent genes, we performed RNA-seq on TSKI4 cells expressing
lentiviral shRNA for Hdac6 (TSKI4H6sh). The intersection of three pairwise comparisons revealed
756 genes that were co-regulated by MAP3K4, CBP, and HDAC6 (Fig. 5a). Moreover, using our
previously published anti-H2BK5Ac ChIP-seq data, we identified genes having reduced
H2BK5Ac in TSKI4 cells relative to TSWT cells41. Among the 756 genes that are co-regulated by
MAP3K4, CBP, and HDAC6, 183 genes had differential H2BK5Ac (Fig. 5a). Functional
enrichment analyses of these 183 genes using Gene Ontology classifications revealed enrichment
of genes in several categories, including Actin Binding, Cytoskeletal Protein Binding, and
Sequence-specific DNA Binding, with 22 (12%) of the 183 genes being TFs (Fig. 5b and
Supplementary Table 1). One goal from these analyses was to identify genes that might act as
broad regulators of cellular programs controlling phenotypic states. Because TFs regulate
expression of many genes, we further analyzed TFs with an RPKM value ³ 0.5 in the above
experiments (Supplementary Fig. 1a). In addition, TFs were analyzed for the degree of change
represented by the RPKM ratio for the following pairwise comparisons: TSKI4/TSWT,
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TSWTCBPsh/TSWT, and TSKI4H6sh/TSKI4. Similarly, H2BK5Ac of gene promoters was represented
as a ratio of TSKI4/TSWT. To prioritize co-regulated TFs, TSKI4/TSWT H2BK5Ac and RNAseq
ratios were ranked using the Wilcoxon rank sum test. Rel showed the most robust decrease in
both transcript and H2BK5Ac in TSKI4 cells relative to TSWT cells (Fig. 5c). Transcripts of TFs
identified by RNAseq were examined using qPCR, confirming that 80% of these genes have
reduced expression in TSKI4 cells relative to TSWT cells (Supplementary Fig. 1b, c). Together,
these data identified a set of TFs that may play key roles in promoting the epithelial state.
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Fig. 5 Analyses of genome wide RNA-seq and ChIP-seq data identify transcription factors
whose expression is MAP3K4, CBP, HDAC6, and H2BK5Ac dependent.
a Bioinformatics analyses of RNA-seq and anti-H2BK5Ac ChIP-seq data from TSWT cells or
TSKI4 cells expressing control shRNA, TSWT cells expressing Crebbp shRNA (TSWTCBPsh) or
TSKI4 cells expressing Hdac6 shRNA (TSKI4H6sh). Venn diagram shows 756 genes whose
expression is MAP3K4, CBP, and HDAC6 dependent. Of these 756 genes, 183 genes are
H2BK5Ac dependent. The cutoff fold change value for differentially expressed genes was £ 0.75
for TSKI4/TSWT and TSWTCBPsh/TSWT and ³ 1.5 for TSKI4H6sh/TSKI4.
b Enrichment of genes encoding DNA-binding proteins. Pie chart depicts the Gene Ontology for
the molecular function annotation of the 183 co-regulated genes. Twelve percent of these genes
are transcription factors (TFs) categorized under sequence-specific DNA binding.
c Table shows differential expression of MAP3K4, CBP, HDAC6, and H2BK5Ac dependent
TFs identified in (b). TFs with ³ 0.5 reads per kilobase of transcript per million mapped reads
(RPKM) in TSWT cells are shown. RNA-seq RPKM values for each sample were expressed as
ratios. For example, RPKM values in TSKI4 cells were divided by those for TSWT cells. AntiH2BK5Ac ChIP-seq values determined using EpiCenter were also expressed as a ratio dividing
values in TSKI4 cells by those for TSWT cells91. TFs were prioritized using the Wilcoxon rank
sum test of TSKI4/TSWT H2BK5Ac ChIPseq and RNAseq ratios.
See also Supplementary Fig. 1.
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Selective loss of the NF-kB family member Rel in TSKI4 cells in EMT
As the highest ranking co-regulated TF, we examined the expression of Rel in TSWT and
TSKI4 cells. Rel is a member of the NF-kB family of TFs consisting of five members. qPCR
showed that Rel was the only NF-kB family member with altered transcript expression in TSKI4
cells (Fig. 6a). Western blotting of cytoplasmic and nuclear lysates showed reduction of REL in
the cytoplasm and complete loss in the nucleus of TSKI4 cells (Fig. 6b). Comparison of
expression and localization of the NF-kB family in TSWT cells showed that RELA and RELB
were localized primarily to the cytoplasm, suggesting that they were inactive (Fig. 6b-d). REL,
p50, and p52 family members were located in the cytoplasm and nucleus with nuclear
localization suggesting active REL, p50, and p52 (Fig. 6b-d). TSKI4 cells showed reduced protein
and loss of nuclear localization of REL and p52 (Fig. 6b-d). Total NF-kB activity was reduced
by > 50% in TSKI4 cells (Fig. 6e). Together, these data suggested that REL functions as the
dominant NF-kB family member in epithelial TS cells.
Removal of FGF4, Heparin, and mouse embryonic fibroblast conditioned media (MEFCM) results in loss of stemness in TS cells, and initiation of EMT with differentiation to a mixed
population of differentiated, mature trophoblasts (TDIFF)41. One subtype of differentiated
trophoblasts has acquired invasiveness (TINV)41. As measured by qPCR, differentiation into
mixed TDIFF resulted in only modest changes in NF-kB family member transcripts (Fig. 6f, g). In
contrast, invasive TINV showed the selective induction of RelA, RelB, and Nfkb2 transcripts,
suggesting a role for these family members in invasive, differentiated trophoblasts (Fig. 6g).
Importantly, Rel and Nfkb1 transcripts were not induced in invasive trophoblasts, consistent with
an opposing role for Rel to promote undifferentiated, epithelial TS cells (Fig. 6f).
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Fig. 6 Selective regulation of REL expression in TS cells.
a Selective reduction of Rel transcript levels in TSKI4 cells relative to TSWT cells. Transcripts of
all NF-kB members were measured by qPCR. The data normalized to Rps11 are expressed as a
fold-change relative to TSWT cells and are the mean ± SEM of five independent experiments.
b Cytoplasm and nuclear protein levels of NFkB members were measured using Western
blotting in TSWT cells and TSKI4 cells. Blots are representative of three independent experiments.
c, d Densitometry was used to quantify cytoplasmic (c) and nuclear (d) NF-kB protein
expression (b) from three independent experiments. Data are expressed as fold-change relative to
TSWT cells and are the mean ± SEM.
e NFkB transcriptional activity is reduced in TSKI4 cells relative to TSWT cells. Luciferase
activity was measured in cells expressing a NF-kB luciferase construct. Data shown are the fold
change in luciferase activity relative to TSWT cells and are the mean ± SEM of three independent
experiments.
f, g NF-kB member transcript levels in undifferentiated TS cells (TSWT), TS cells differentiated
for 4 days (TDIFF), and invasive trophoblasts (TINV) were measured using qPCR. The data
normalized to Gapdh are expressed as a fold-change relative to undifferentiated TSWT cells and
are mean ± range of two independent experiments.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
(n.s., not significant).
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Induction of REL expression in TSKI4 cells promotes mesenchymal to epithelial transition
To examine the role of Rel in controlling the cellular phenotype, TSKI4 cells were infected
with a doxycycline-inducible construct expressing human REL and selected for stable
transduction using puromycin. Addition of doxycycline (Dox) to cells transduced with human
REL (TSKI4R cells) resulted in modest expression of REL (Supplementary Fig. 2a, b). Previous
work has demonstrated that methylation of lentiviral promoters can silence transgene expression,
and inhibition of DNA methyltransferases can allow transgene expression92, 93. Transient
inhibition of DNA methyltransferases for 48 hours with 5-Aza-2’-Deoxycytidine (Aza) in TSKI4R
cells did not affect expression of human REL transcript or protein (Supplementary Fig. 2a, b).
However, the combined addition of Aza for 48 hours and Dox for 96 hours resulted in robust
increases in both human REL transcript and protein measured using human Rel specific primers
and antibody, respectively (Supplementary Fig. 2a, b). Further, transient co-treatment of TSKI4R
cells with Aza and Dox was sufficient to induce a phenotypic switch from mesenchymal-like
cells to cells having an epithelial-like morphology (Supplementary Fig. 2c). These data
suggested that the induction of Rel expression maybe sufficient to induce MET.
To study the effects of REL re-expression, we grew TSKI4R cells continuously in the
absence or presence of Dox. TSKI4R cells grown in Dox showed robust expression of human REL
transcript and protein (Fig. 7a, b). Importantly, TSKI4R cells grown in Dox showed a stable,
epithelial morphology compared to TSKI4R cells cultured in the absence of Dox (Fig. 7c). TSKI4R
cells grown without Dox showed decreased expression of epithelial markers and increased
expression of mesenchymal markers and EMT-inducing TFs relative to TSWT cells (Fig. 7d-g).
Culture of TSKI4R cells continuously in Dox induced re-expression of epithelial markers (Fig. 7d,
Supplementary Fig. 2d, e). Although expression of the mesenchymal marker Vim was only
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partially decreased by REL re-expression, expression of Cdh2 and EMT-inducing TFs Snai2,
Twist1, and Zeb1 were returned to low levels observed in TSWT cells (Fig. 7e-g). Mesenchymallike TSKI4 cells show increased invasiveness and decreased barrier function relative to epithelial
TSWT cells (Fig. 7h, i). REL re-expression in Dox treated TSKI4R cells repressed cellular invasion
and promoted barrier function (Fig. 7h, i). Together, these data indicated that REL re-expression
induced a phenotypic change from mesenchymal to epithelial.
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Fig. 7 Induction of REL expression in mesenchymal-like TSKI4 cells promotes an epithelial
phenotype.
a Human REL transcript levels were measured in uninduced and Doxycycline (Dox) induced
TSKI4 cells transduced with lentiviral constructs expressing Tet-on-human REL (TSKI4R) using
qPCR and human specific REL primers.
b REL protein expression was measured using Western blotting with anti-human specific REL
antibody. Blots of whole cell lysates are representative of three independent experiments.
c Dox induced REL expression restores an epithelial morphology in TSKI4 cells re-expressing
REL (TSKI4R) cells. Representative phase microscopy images for three independent experiments
are shown. Scale bar represents 400 µm.
d REL expression in TSKI4 cells increased transcripts of epithelial markers.
e, f, g Reduced mesenchymal markers (e, f) and EMT-inducing TFs (g) transcripts upon REL reexpression.
a, d-g Transcripts were measured using qPCR. The data normalized to Rps11 are expressed as a
fold-change relative to TSWT cells and are the mean ± SEM of three independent experiments.
h Invasion through growth factor reduced Matrigel was decreased in Dox induced TSKI4R cells
relative to uninduced TSKI4R cells. Data show the mean ± range of two independent experiments
performed in triplicate.
i Barrier formation is increased in TSKI4 cells after REL re-expression. Data show the fold
change in fluorescence of diffused dye relative to TSWT cells and are the mean ± SEM of three
independent experiments.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
(n.s., not significant).
See also Supplementary Fig. 2 .
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Constitutive expression of REL restores the epithelial phenotype in TSKI4 cells.
We also examined the impact of REL re-expression using a construct that constitutively
expresses REL. Similar to Dox-induced REL expression, constitutive expression of REL in two
different clones of TSKI4 cells (TSKI4R1 and TSKI4R2) induced an epithelial morphology (Fig. 8a,
b). TSKI4R1 and TSKI4R2 cells re-expressed epithelial markers and showed reduced expression of
mesenchymal markers and EMT-inducing TFs (Fig. 8c-e). Expression of REL from the
constitutive promoter also repressed invasion and partially restored barrier formation (Fig. 8f, g).
Microarray analyses of upregulated genes in TSKI4R cells relative to control infected TSKI4 cells
showed enrichment for genes in several categories important for cellular morphology, including
Focal adhesion and Cell-substrate adherens junction (Fig. 8h). Together, these data suggested
that Rel re-expression in TSKI4 cells induces MET.
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Fig. 8 REL re-expression using a constitutive promoter restores the epithelial phenotype in TSKI4
cells.
a Human REL expression analyzed in TSWT cells, TSKI4 cells and TSKI4 cells transduced with
lentiviruses expressing human REL under a constitutive promoter (TSKI4R1 and TSKI4R2 cells)
representing two independent clones. Western blotting analysis of nuclear lysates was performed
using anti-human specific REL antibody. Blots are representative of three independent
experiments.
b TSKI4R1 and TSKI4R2 cells display an epithelial morphology. Representative phase microscopy
images from three independent experiments are shown. Scale bar represents 400 µm.
c Increased expression of epithelial markers at transcript level in TSKI4R1 and TSKI4R2 cells.
d, e REL re-expression reduces mesenchymal markers and EMT-inducing TFs.
c-e Transcripts were measured using qPCR. The data normalized to Actb are expressed as a foldchange relative to TSWT cells and are mean ± SEM of three independent experiments.
f Expression of REL under a constitutive promoter decreases invasiveness in TSKI4R1 and TSKI4R2
cells relative to TSKI4 cells. Data show the mean ± range of two independent experiments
performed in triplicate.
g Barrier formation is restored upon re-expression of REL in TSKI4 cells as measured by
fluorescent dye exclusion assays. Data show relative fluorescence compared to TSWT cells and
represent the mean ± SEM of four independent experiments.
h Cellular component functional annotation of microarray data from TSKI4 cells and TSKI4 cells
expressing human REL under a constitutive promoter (TSKI4R cells). Genes whose expression is
upregulated in TSKI4R cells relative to TSKI4 cells were analyzed using a cut-off (log2(foldchange) ³ 2 and FDR < 0.05.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
(n.s., not significant).
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Expression of RELB in TSKI4 cells switches cells to a fully mesenchymal state
We wondered if the effects of REL expression on TSKI4R cells were selective for REL, or
if other NF-kB family members would have a similar effect. We infected TSKI4 cells with
lentivirus encoding human RELB and selected for stable expression using puromycin (TSKI4RB
cells). Human RELB expression was detected both at transcript and protein levels in TSKI4RB cells
(data not shown and Fig. 9a). Expression of RELB induced the transition of TSKI4RB cells to an
entirely mesenchymal state (Fig. 9b). Consistent with changes in morphology, TSKI4RB cells
showed the near complete loss of epithelial markers Cdh1 and Cldn6 (Fig. 9c). Further, Vim,
Cdh2, and EMT-inducing TF expression were increased in TSKI4RB cells relative to TSKI4 cells
(Fig. 9d-f). In addition, invasiveness in TSKI4RB cells was greater than TSKI4 cells, and barrier
formation remained impaired (Fig. 9g, h). These data showed that expression of RELB in TSKI4
cells induced a complete EMT. Together, these data demonstrated the selectivity of NF-kB
family members in control of TS cell phenotypic states.
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Fig. 9 Expression of RELB in TSKI4 cells induces EMT.
a RELB protein levels were measured in TSWT cells, TSKI4 cells, and TSKI4 cells expressing
RELB (TSKI4RB) cells. Western blots of nuclear lysates are representative of two independent
experiments.
b RELB expression induces a mesenchymal morphology in TSKI4R cells. Representative phase
microscopy images for three independent experiments are shown. Scale bar represents 400 µm.
Arrows show the area of enlarged insets.
c RELB expression in TSKI4 cells results in loss of epithelial marker expression.
d-f Increased transcripts of mesenchymal markers (d, e) and EMT-inducing TFs (f) upon RELB
expression.
c-f Transcripts were measured using qPCR. The data normalized to Rps11 are expressed as foldchange relative to TSWT cells and are the mean ± SEM of three independent experiments.
g Invasion through growth factor reduced Matrigel was increased in TSKI4RB cells relative to
TSKI4 cells. Data show the mean ± range of two independent experiments performed in triplicate.
h Barrier formation shown as the fold change in fluorescence of diffused dye relative to TSKI4
cells. Data are expressed as the mean ± SEM of three independent experiments.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
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CBP directly binds promoter and predicted enhancer regions of Rel
Based on our new RNA-seq data and previously published anti-H2BK5Ac ChIP-seq data,
we identified Rel as a MAP3K4, CBP, HDAC6, and H2BK5Ac co-regulated gene. To determine
if the effects of CBP on Rel expression are through direct binding to and control of the Rel gene,
we examined Rel expression in TSWT cells and TSWT cells expressing shRNAs for Crebbp
(TSWTCBPsh1 and TSWTCBPsh2). Expression of lentiviral shRNAs for Crebbp resulted in an 82%
reduction in Crebbp transcript (Fig. 10a). CBP knockdown in TSWTCBPsh1 and TSWTCBPsh2 cells
reduced Rel transcript and protein relative to TSWT cells (Fig. 10b-d). Rel was the only NF-kB
family member whose expression was decreased with CBP knockdown (Fig. 10b-d). To
determine if CBP bound the Rel promoter, we performed chromatin immunoprecipitations with
anti-CBP antibody. We measured a 15-fold enrichment of CBP on the Rel promoter (-700)
compared to isotype control IgG antibody (Fig. 10e). Enrichment of CBP on the Rel promoter
was decreased in TSKI4 cells relative to TSWT cells (Fig. 10f). These data suggested that CBP is
bound to the Rel promoter and loss of MAP3K4 kinase activity results in decreased binding of
CBP to the Rel promoter.
CBP has been shown to bind enhancer regions of many genes with CBP promoting gene
expression57. In Fig. 10, we showed that CBP is bound to the Rel promoter. We wondered if CBP
was also bound to enhancer regions for Rel. To identify putative enhancer regions, we examined
contact maps from previously published promoter capture Hi-C data from wild-type TS cells55.
We chose fourteen sites based on number of reads and distance from the Rel transcription start
site (Supplementary Fig. 3a, b). Four of these sites were found in predicted promoters
(Supplementary Fig. 3a, b). For the other sites, two were located upstream of the Rel promoter
and eight were found downstream (Supplementary Fig. 3a, b). H3K27Ac marks promoters and

54

active enhancers94. Comparison of isotype control IgG ChIP to anti-H3K27Ac ChIP at several of
these sites revealed a 9 to 40-fold increase in enrichment in H3K27Ac at these sites
(Supplementary Fig. 3c). Using anti-H3K27Ac ChIP-PCR, we compared H3K27Ac at all regions
in TSKI4 cells relative to TSWT cells. H3K27Ac did not change between TSKI4 cells and TSWT
cells for most of the contact sites suggested by promoter capture Hi-C data (Supplementary Fig.
3d, e). For promoters predicted to contact the Rel promoter, we observed only very modest
decreases in H3K27Ac in TSKI4 cells relative to TSWT cells (Supplementary Fig. 3d). The only
exception was the predicted promoter for Gm12061-001. In contrast, there were dramatic
changes in H3K27Ac at several potential enhancer sites predicted using promoter capture Hi-C.
Surprisingly, the site -37106 bp upstream of the Rel promoter showed a two-fold increase in
H3K27Ac in TSKI4 cells relative to TSWT cells (Supplementary Fig. 3e). In contrast, a region
found between +29050 to +35817 bp downstream of the Rel promoter showed approximately a
50% decrease in H3K27Ac in TSKI4 cells relative to TSWT cells (Supplementary Fig. 3e).
H3K27Ac of an additional region located between +83091 and +101930 downstream of the Rel
promoter was also significantly decreased in TSKI4 cells relative to TSWT cells (Supplementary
Fig. 3e). Based on diminished H3K27Ac in TSKI4 cells relative to TSWT cells, proximity to the
Rel promoter, and contacts with the Rel promoter as measured by promoter capture Hi-C, we
predicted that the region between +29050 to +35817 bp may serve to enhance Rel expression.
We measured a 12-16 fold enrichment of CBP at these sites relative to isotype control IgG
antibody, suggesting CBP was bound to these sites in TSWT cells (Fig. 10e). However, anti-CBP
ChIP PCR comparing CBP enrichment in TSKI4 cells relative to TSWT cells did not show
differences in CBP binding at these sites (Fig. 10f). Together, these data suggested that CBP is
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bound to these putative Rel enhancer sites but altered binding of CBP was not responsible for
changes in H3K27Ac at these sites in TSKI4 cells relative to TSWT cells.

Fig. 10 CBP promotes REL expression in TS cells.
a Crebbp transcripts levels were measured in TSWT cells and TSWT cells expressing two
independent Crebbp shRNAs (TSWTCBPsh1 and TSWTCBPsh2) using qPCR.
b shRNA knockdown of CBP results in decreased Rel transcripts measured using qPCR.
c Transcript levels of the other NF-kB members were measured using qPCR.
a-c qPCR data normalized to Rps11 are expressed as a fold-change relative to TSWT cells and are
the mean ± SEM of three independent experiments.
d CBP knockdown results in reduced REL protein expression. Western blots are representative
of three independent experiments.
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Fig. 10 (continued)
e CBP enrichment on the Rel promoter (-700) and predicted enhancer regions (+29050, +33455
and +35817) was measured using anti-CBP ChIP-PCR. Data are expressed as a fold change in
enrichment of anti-CBP ChIP relative to anti-IgG ChIP. Data represent the mean ± range of two
independent experiments.
f Anti-CBP ChIP-PCR shows decreased CBP enrichment on the Rel promoter in TSKI4 cells
relative to TSWT cells. Experiments were performed as in (e). Data show the mean ± SEM of
three independent experiments.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
(n.s., not significant).
See also Supplementary Fig. 3.
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HDAC6 binds directly to promoter and predicted enhancer regions of Rel to repress histone
acetylation
We have previously shown that Hdac6 expression and activity are increased in TSKI4
cells relative to TSWT cells64. As shown in Fig. 11a, Hdac6 transcripts were increased in TSKI4
cells. shRNA knockdown of Hdac6 in TSKI4H6sh cells reduced Hdac6 transcripts to levels lower
than TSWT cells (Fig. 11a). TSKI4H6sh cells had increased Rel transcripts and protein (Fig. 11b, c).
Treatment of TSKI4 cells with the HDAC6 selective inhibitor Tubastatin also increased Rel
transcripts (Fig. 11d). Together, these data suggested that HDAC6 represses Rel expression.
We have previously shown that HDAC6 is found in the nuclei of TSKI4 cells64. To
determine if HDAC6 directly regulates the expression of Rel, we performed anti-HDAC6 ChIPPCR. HDAC6 was enriched on the Rel promoter and predicted enhancer regions in TSKI4 cells,
and knockdown of Hdac6 reduced enrichment (Fig. 11e, Supplementary Fig. 3f). These data
suggested that HDAC6 is physically bound to the regulatory regions of Rel. We have previously
demonstrated that HDAC6 reduces total H2BK5Ac in TSKI4 cells64. Consistent with these
findings, total H2BK5Ac was reduced in TSKI4 cells, and shRNA knockdown of Hdac6 restored
H2BK5Ac (Fig. 11f). Anti-H2BK5Ac ChIP-PCR showed reduced H2BK5Ac at the promoter
and predicted enhancer regions of Rel in TSKI4 cells (Fig. 11g). Acetylation of these sites was
HDAC6 dependent, because knockdown of Hdac6 restored H2BK5Ac to wild-type levels (Fig.
11g). Based on changes in H3K27Ac on predicted enhancer regions in TSKI4 cells relative to
TSWT cells, we examined total H3K27Ac, finding drastically diminished total H3K27Ac in TSKI4
cells that was restored to wild-type levels by knockdown of Hdac6 (Fig. 11f). Consistent with
these findings, H3K27Ac on the Rel promoter was reduced and knockdown of Hdac6 restored
H3K27Ac (Fig. 11h). However, loss of Hdac6 had only modest but statistically significant
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effects on H3K27Ac at predicted Rel enhancer regions (Fig. 11h). Together, these data suggest
that HDAC6 represses Rel expression by promoting the deacetylation of both H2BK5 and
H3K27 on Rel regulatory regions.
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Fig. 11 HDAC6 regulates Rel expression by controlling H2BK5Ac and H3K27Ac on the Rel
promoter and predicted enhancer regions.
Fig. 11 (continued)
a Hdac6 transcript levels in TSWT cells and TSKI4 cells expressing control shRNA (C) or TSKI4
cells expressing Hdac6 shRNA (TSKI4H6sh) were measured using qPCR.
b HDAC6 knockdown in TSKI4H6sh cells increases Rel transcript levels relative to TSKI4 cells.
c HDAC6 knockdown increases REL protein expression. Western blots of whole cell lysates are
representative of three independent experiments.
d Inhibition of HDAC6 activity using Tubastatin A partially restores Rel expression at transcript
level in TSKI4 cells. Cells were treated for 48 hours with DMSO (0) or 10 µM Tubastatin A.
a,b,d qPCR data normalized to Rps11 are the mean ± SEM of three independent experiments.
e Anti-HDAC6 ChIP-PCR shows increased HDAC6 enrichment on the Rel promoter and
predicted enhancer regions in TSKI4 cells relative to TSWT cells. Data shown are the mean ± SEM
of three independent experiments.
f HDAC6 knockdown restores total H2BK5Ac and H3K27Ac in TSKI4 cells. Western blots are
representative of three independent experiments.
g H2BK5Ac of the Rel promoter and predicted enhancer regions is completely restored upon
HDAC6 knockdown in TSKI4 cells as measured by anti-H2BK5Ac ChIP-PCR.
h H3K27Ac is completely restored on the Rel promoter as measured by anti-H3K27Ac ChIPPCR.
g,h Data shown are the mean ± SEM of three independent experiments.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
See also Supplementary Fig. 3.
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REL re-expression promotes the re-expression of MAP3K4, CBP, HDAC6, and H2BK5Ac coregulated transcription factors
A key remaining question was the mechanism by which REL re-expression in
mesenchymal-like TSKI4 cells induced MET. Further, how does RELB expression induce EMT?
Previous studies have demonstrated the critical importance of NF-kB induction of inflammatory
proteins to promote EMT95, 96. Thus, one possible explanation for the outcomes of REL versus
RELB expression on the cellular phenotype of TSKI4 cells maybe differences in expression of
inflammatory proteins. Examination of RNAseq data revealed the expression of very few genes
encoding inflammatory cytokines or their receptors (Supplementary Table 2). However, we
noted modest changes in the transcripts for Tnf and Tnfsf12 (TWEAK) and their receptors in
TSKI4 cells relative to TSWT cells (Supplementary Table 2). As measured by qPCR, REL
expression did not induce the expression of Tnf or Tnfsf12 (Supplementary Fig. 4). In contrast,
RELB expression induced a robust increase in both Tnfsf12 and its receptor Tnfrsf12a,
suggesting that EMT induction by RELB expression may involve expression of inflammatory
cytokines and receptors (Supplementary Fig. 4).
Since REL re-expression in TSKI4 cells did not induce inflammatory proteins, we
wondered if REL re-expression induced MET by influencing the expression of the other fourteen
TFs co-regulated by MAP3K4, CBP, and HDAC6 (Fig. 5c). Examination of microarray data
from TSKI4R cells constitutively re-expressing REL revealed that 71% (10/14) of the co-regulated
TFs were also re-expressed in TSKI4R cells relative to control TSKI4 cells (Fig. 12a). However,
expression of only three TFs, Ets1, Hivep2, and Id2, was statistically significant (Fig. 12a). To
further examine the impact of REL re-expression on the expression of these other TFs, we
performed qPCR. Although we were unable to detect Lhx6 using multiple primer pairs, we found
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expression of ten of the fourteen co-regulated TFs was increased in two individual TSKI4 cell
clones re-expressing REL (TSKI4R1 and TSKI4R2 cells) (Fig. 12b-d). Some TFs like Hoxa1 and
2610008E11Rik were only very modestly changed (Fig. 12d). However, expression of many of
these TFs was restored to TSWT cell levels (Fig. 12b-d). Further, transcripts for Ets1 and Zfp672
were 3-4 fold higher in TSKI4R cells than TSWT cells (Fig. 12b). These data suggested that REL
controlled the expression of most of the MAP3K4, CBP, HDAC6, and H2BK5Ac co-regulated
TFs.
REL re-expression promotes MET by binding to the Hdac6 promoter and reducing nuclear
HDAC6 protein levels
Because REL promoted the re-expression of most of the co-regulated TFs, we wondered
if REL controlled the expression of the histone modifiers CBP and/or HDAC6. As measured by
qPCR, REL re-expression did not induce Crebbp expression (Fig. 12e). However, both inducible
and constitutive expression of REL resulted in decreased Hdac6 transcript (Fig. 12f, g).
Although HDAC6 protein expression remained elevated in the cytoplasm of TSKI4R cells, nuclear
localization of HDAC6 was dramatically reduced in Dox induced TSKI4R cells relative to
untreated TSKI4R cells (Fig. 12h). Western blotting of whole cell lysates showed decreased total
HDAC6 protein in cells re-expressing REL (Fig. 12i). Together, these data indicated that REL
expression altered HDAC6 expression and localization. To determine if REL directly controls
HDAC6 expression, we performed anti-REL ChIP-PCR. Although REL was not enriched on the
Hdac6 promoter in TSKI4 cells, REL was enriched five-fold on the Hdac6 promoter in TSWT cells
relative to isotype control IgG (Fig. 12j). Together, these data suggest that REL expression
induces a phenotypic switch from mesenchymal to epithelial in part by repressing HDAC6
expression.
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Fig. 12 REL re-expression induces MET by decreasing nuclear HDAC6 levels and increasing the
expression of MAP3K4, CBP, and HDAC6 co-regulated transcription factors.
a REL re-expression in TSKI4R cells promotes the re-expression of co-regulated TFs. Microarray
data from TSKI4 cells and TSKI4 expressing human REL under a constitutive promoter (TSKI4R
cells) were examined for expression changes in co-regulated TFs. Data are expressed as a log2
fold change in TSKI4R cells relative to TSKI4 cells. Statistical significance of fold changes
expressed as p-values was determined using a one-way ANOVA.
b-d Increased transcript levels for most of the co-regulated TFs upon re-expression of REL.
Control infected TSWT cells and TSKI4 cells, or two independent clones of TSKI4 cells
constitutively expressing REL TSKI4R1 and TSKI4R2 cells were examined. qPCR data show the
mean ± range of two independent experiments performed in triplicate.
e Crebbp expression in TSKI4 cells constitutively expressing REL. qPCR show the mean ± SEM
of three independent experiments.
f Hdac6 expression in TSKI4 cells expressing an inducible Rel construct. qPCR show the mean ±
SEM of three independent experiments.
g Hdac6 expression in TSKI4 cells constitutively expressing REL. qPCR data show the mean ±
SEM of three independent experiments.
h Decreased HDAC6 protein in the nuclei of TSKI4R cells re-expressing REL. Protein expression
was measured in cytoplasmic and nuclear extracts. Data show representative images from three
independent experiments.
i Decreased total HDAC6 protein in TSKI4 cells constitutively expressing REL measured using
Western blotting of whole cell lysates. Data show representative images from two independent
experiments.
j Anti-REL ChIP-PCR shows increased enrichment of REL relative to isotype control IgG on the
Hdac6 promoter in TSWT cells. Data shown are the mean ± SEM of four independent
experiments.
See also Supplementary Fig. 4.
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DISCUSSION
Herein, we define an epigenetic program controlling phenotypic switching in stem cells from
mesenchymal to epithelial states. MAP3K4, CBP, and HDAC6 coordinate the expression of a
specific set of genes to regulate phenotype. We demonstrate the key role of the co-regulated
gene, Rel, in inducing the epithelial state. Mesenchymal-like TS cells deficient in MAP3K4
kinase activity have reduced Rel expression, and re-expression of REL induces a mesenchymal
to epithelial switch. This effect is selective for REL, as expression of RELB in TSKI4 cells
induces a fully mesenchymal state. CBP and HDAC6 bind directly to the regulatory regions of
Rel, controlling the acetylation of histones H2BK5 and H3K27. In addition to the epigenetic
regulation of Rel by CBP and HDAC6, we show a reciprocal regulation of HDAC6 where REL
functions to repress HDAC6. Together, our work defines an epigenetic program that coordinates
gene expression for controlling phenotypic switching between mesenchymal and epithelial
states.
We have discovered previously unidentified roles for NF-kB family members in TS cells
isolated from mouse pre-implantation blastocysts. We have found that Rel expression in
mesenchymal-like TS cells induces MET. In contrast, expression of Relb induces EMT, and Relb
is upregulated at transcript levels in TS cells that have differentiated into invasive trophoblasts.
Together, our data show selective roles for NF-kB family members in TS cells. Previous work
has shown the presence of Rel, Rela, Relb, and NFkB1 transcripts in mouse oocytes, and twocell, eight-cell, and blastocyst stage embryos97. In cultured mouse embryonic stem (ES) cells
isolated from blastocysts, total NF-kB activity is inhibited and differentiation of ES cells induces
NF-kB activity98. Mouse ES cells express very low levels of REL, and overexpression of REL in
mouse ES cells induces differentiation and a dramatic loss of the epithelial state99. Similar to ES
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cells, we show that TS cells express all five NF-kB family members. However, based on nuclear
localization, REL is the primary active family member in TS cells. Differentiation of TS cells to
invasive trophoblasts specifically induces the expression of Rela, Relb, and NF-kB2, suggesting
selective roles for NF-kB family members in invasive trophoblasts. Unlike ES cells where REL
overexpression induces differentiation, re-expression of REL in cells with a mesenchymal
phenotype promotes an epithelial phenotype, suggesting a different role for REL in TS cells. Our
examination of published anti-CDX2 and anti-EOMES ChIP-seq data revealed binding of both
stemness promoting TFs to the promoter of Rel in wild-type TS cells36, 100-102. These findings are
consistent with Rel expression in TS cells and a role for Rel in promoting the epithelial
phenotype101, 102. Evaluation of anti-H3K4me3 and anti-H3K27me3 ChIP-seq data from RuggGunn et al. showed the presence of repressive H3K27me3 marks on the Rel promoter in mouse
ES cells that is absent in TS cells103. In contrast, the Rel promoter is enriched for active
H3K4me3 marks in TS cells103. These findings are consistent with the lack of Rel expression in
ES cells, and the presence of Rel expression in TS cells. Together, these results indicate very
different roles for REL in embryonic ES cells versus extraembryonic TS cells.
Although we and others have defined the roles of NF-kB family members in cells from
blastocysts, it has been difficult to define their roles during development. The use of simpler
model organisms, including Drosophila, Xenopus laevis, and Danio rerio has enabled
identification of the critical role of NF-kB in developmental programs like embryonic dorsalventral patterning69. Success of studies in Drosophila is due in part to having fewer NF-kB
family members77. However, it has been extremely difficult to establish the precise roles of
individual NF-kB family members during development in higher organisms. One limitation has
been the relatively low numbers of phenotypes that occur with single deletion of NF-kB family
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members in mice69, 80. The ability of family members to bind similar kB sites creates the
potential for functional redundancy and compensation 71, 104. Signaling complexity is created by
their ability to function as homodimers and heterodimers. Further, the family members often
have opposing roles, and deletion of one member may induce a phenotype created by activity of
another member 69, 105, 106. Although single deletion of RelA, Ikkb, or NEMO results in embryonic
lethality, deletion of two family members leads to more deleterious phenotypes with earlier
onset. For example, the single deletion of RelA in mice results in embryonic lethality at E15 due
to liver degeneration 107, 108. However, co-deletion of RelA and Rel results in lethality at E13.5 66.
Earlier onset suggests the ability of Rel to compensate for loss of RelA. It has been suggested by
numerous investigators that the broad capacity of theses NF-kB family members to devise
mechanisms to compensate for the loss of a member has resulted in difficulties in defining the
key role of these TFs in development 68, 69, 71, 79. Analysis of more complex genetic alterations of
NF-kB family members in mice has established roles for NF-kB family members in neural tube
closure, and in the development of the lung, muscle, skin, skeleton, and hematopoietic system69.
Using TSKI4 cells isolated from mice with the targeted inactivation of MAP3K4, we have
dissected the specific role of Rel in TS cells. Although all members are expressed, NF-kB family
members cannot compensate for loss of Rel in undifferentiated TS cells. This lack of
compensation may be due to the role of RELA and RELB in differentiated, invasive
trophoblasts.
Our new work demonstrates that Rel transcript levels are epigenetically regulated during
phenotypic switching in TS cells. These finding contrasts strongly with constitutive expression
of NF-kB family members in the majority of cell types104. NF-kB is primarily regulated at the
level of activity by controlling the translocation of constitutively expressed NF-kB dimers
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between the cytoplasm and nucleus104. Here, we define a MAP3K4, CBP and HDAC6 dependent
epigenetic mechanism regulating Rel transcript expression during EMT and MET. We have
previously shown that active MAP3K4 induces CBP activity and inhibits HDAC6 expression
and activity41, 64. Loss of MAP3K4 activity results in decreased CBP activity and elevated
HDAC6 expression and activity41, 64. We show that CBP binds to Rel regulatory regions,
including promoter and predicted enhancer regions and promotes Rel expression. Importantly,
loss of MAP3K4 activity in mesenchymal-like TSKI4 cells reduces binding of CBP to the Rel
promoter and decreases the expression of Rel41. Consistent with these findings, knockdown of
CBP expression in epithelial TSWT cells induces a mesenchymal phenotype and decreases the
expression of Rel. Further we show that HDAC6 represses Rel expression by direct binding to
Rel regulatory regions and decreasing H2BK5 and H3K27 acetylation on both Rel promoter and
predicted enhancer regions. Although we have previously shown that HDAC6 deacetylates
H2BK5 on promoters of epithelial genes, a role for HDAC6 in deacetylation of H2BK5 on
enhancers has not been previously demonstrated64. Further, we identify a previously unknown
role for HDAC6 in deacetylation of H3K27 on both promoters and distal regulatory regions.
Together, our work defines a mechanism for epigenetic co-regulation of Rel expression by CBP
and HDAC6, controlling phenotypic switching.
NF-kB family members have been shown to regulate EMT in several systems, especially
in cancer109, 110. Induction of EMT by NF-kB is often dependent on expression of inflammatory
cytokines and their receptors95, 96, 111. In this inflammatory context, NF-kB promotes the
expression of several EMT-inducing TFs, including Snai1, Snai2, Twist1, Zeb1, and Zeb2106, 111115

. Similarly, expression of RELB in TSKI4 cells induces EMT, promoting expression of Snai2,

Twist1, and Zeb1 and repression of Cdh1. Further, RELB expression in TSKI4 cells strongly
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induces the expression of the inflammatory genes Tnfsf12 and Tnfrsf12a, consistent with the
induction of EMT by RELB in these cells. In contrast, REL expression induces MET.
Importantly, REL expression in TSKI4 cells does not induce the expression of inflammatory
proteins or EMT. Instead, REL promotes the expression of CBP and HDAC6 co-regulated TFs.
Our findings are consistent with a recent study identifying Rel as one of the top 25 TFs whose
expression correlated with MET116. An additional mechanism by which REL induces MET may
be through repression of HDAC6 where REL binds the Hdac6 promoter in TSWT cells. This
binding was not detectable in TSKI4 cells that overexpress Hdac6. Our findings suggest that REL
may act as a physical repressor of Hdac6 expression, preventing HDAC6 induction of EMT. Coregulation of Rel expression by CBP and HDAC6 coupled to the regulation of Hdac6 expression
by REL provides a coordinated biological program to control switching between different
phenotypic states.
In summary, we define an epigenetic program that controls switching between epithelial,
intermediate, and mesenchymal states in TS cells. In this program, MAP3K4, CBP, and HDAC6
coordinate gene expression for selection of phenotypic states. Rel is a key regulator of the
phenotypic state whose expression is controlled by direct binding of CBP and HDAC6 to Rel
regulatory regions. We also demonstrate the reciprocal regulation by REL of TFs co-regulated by
CBP and HDAC6. Further, REL represses the chromatin modifier HDAC6 through direct
binding to the Hdac6 promoter. Together, our work provides insight into the mechanisms
controlling cellular decisions to establish different phenotypes.
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Supplementary Figures
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Supplementary Fig. 1 Validation of expression of MAP3K4, CBP, HDAC6 and H2BK5Ac
dependent transcription factors in TS cells. Related to Fig. 5
a Table shows reads per kilobase of transcript per million mapped reads
(RPKM) from RNA-seq data for TFs co-regulated by MAP3K4, CBP, HDAC6, and H2BK5Ac.
RNA-seq data was measured in TSWT cells or TSKI4 cells expressing control shRNA, TSWT cells
expressing Crebbp shRNA (TSWTCBPsh) or TSKI4 cells expressing Hdac6 shRNA (TSKI4H6sh).
b, c Validation of expression changes of TFs with RPKM value ³ 0.5 in TSWT cells using qPCR
in TSWT cells and TSKI4 cells. The data normalized to Actb (b) or Rps11 (c) are expressed as a
fold-change relative to TSWT cells and are the mean ± range of two independent experiments.
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Supplementary Fig. 2 Transient re-expression of REL in TSKI4 cells. Related to Fig. 7
a Human REL transcripts were measured in TSKI4 cells transduced with lentiviral constructs
expressing Tet-on-human REL. Cells were cultured for 96 hours as follows: in the absence of
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Doxycycline (Dox) and 5-aza-2'-deoxycytidine (Aza), in the presence of 1 µM Aza for 48 hours,
in the presence of 2 µg/ml Dox for 96 hours, or in the
Supplementary Fig. 2 (continued)
presence of 1 µM Aza for 48 hours and 2 µg/ml Dox for 96 hours. Transcripts were measured
using qPCR and human specific Rel primers. qPCR data show the mean ± range of two
independent experiments.
b REL protein expression was measured using Western blotting and anti-human specific REL
antibody. Blots of whole cell lysates derived from cells treated as in (a) are representative of
three independent experiments.
c Morphological changes induced by transient re-expression of REL in TSKI4 cells. Cells were
either treated with DMSO or treated with 1 µM Aza for 48 hours and 2 µg/ml Dox for 96 hours.
Representative phase microscopy images from three independent experiments are shown. Scale
bar represents 400 µm.
d Representative Western blots from three independent experiments are shown.
e E-cadherin expression and localization in TSWT cells, TSKI4R cells transduced with lentiviral
constructs expressing Tet-on-human REL cells cultured in the absence (-Dox) or presence
(+Dox) of Doxycycline. Cells were stained with anti-E-cadherin antibody (green) and DAPI
nuclear stain (blue). Images are representative of three independent experiments. Scale bar
represents 100 µm.
***p-value < 0.001, ****p-value < 0.0001; Student’s t test. (n.s., not significant).
Western blots show cropped images. Uncropped images are available in Supplementary
Materials.
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Supplementary Fig. 3 Examination of predicted enhancer regions for Rel gene based on
promoter capture Hi-C data using anti-H3K27Ac ChIP PCR. Related to Fig. 10 and Fig. 11
a Schematic diagram of Rel locus. The arrows indicate locations of distal regions interacting
with Rel promoter, labeled from (a-o) based on promoter capture Hi-C data in TS cells.
b Table shows the region coordinates from the mm10 mouse genome, number of reads for the
interactions called by GoTHiC from TS cell promoter capture Hi-C data, and distance from Rel
transcription start site (TSS).
c Enrichment of H3K27Ac on the Rel promoter and predicted enhancers in TSWT cells compared
to an isotype control IgG antibody was measured using anti-H3K27Ac and anti-IgG ChIP-PCR,
respectively. Data shown are the mean ± range of two independent experiments.
d, e Enrichment of H3K27Ac in TSKI4 cells relative to TSWT cells was measured using antiH3K27Ac ChIP-PCR. Fourteen sites were predicted by promoter capture Hi-C data to interact
with the Rel promoter. These sites were examined by anti-H3K27Ac ChIP-PCR. Data are
expressed as a fold change in TSKI4 cells relative to TSWT cells. Sites were categorized as
promoters (d) or putative enhancer regions (e). Data are the mean ± range of two independent
experiments.
f Enrichment of HDAC6 on the Rel promoter in TSKI4 cells compared to an isotype control IgG
antibody was measured using anti-HDAC6 and anti-IgG ChIP-PCR, respectively. Data shown
are the mean ± range of two independent experiments.
*p-value < 0.05; **p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
(n.s., not significant).
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Supplementary Fig. 4 REL expression in TSKI4R cells does not induce the expression of
inflammatory cytokines or their receptors. Related to Figure 12.
a Transcript expression of inflammatory cytokines, Tnf and Tnfsf12, in TSKI4 cells constitutively
expressing REL (TSKI4R) and TSKI4 cells constitutively expressing RELB (TSKI4RB).
b Transcript expression of cytokine receptors, Tnfrsf1a and Tnfrsf12a, in TSKI4R and TSKI4RB
cells.
a, b Transcripts were measured using qPCR. The data normalized to Rps11 are expressed as a
fold-change relative to TSWT cells and are mean ± SEM of three independent experiments.
***p-value < 0.01; ***p-value < 0.001, ****p-value < 0.0001; Student’s t test.
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Chapter III
Conclusion
Herein, we define an epigenetically regulated program for controlling phenotypic
switching in stem cells. This program uses CBP to promote and HDAC6 to represses the
expression of a small group of genes by regulating histone acetylation on both promoter and
enhancer regions. Surprisingly, one of these co-regulated genes is the NF-kB family member
Rel. Expression of Rel is sufficient to drive the switch from mesenchymal to epithelial
phenotype. In this program, REL provides reciprocal regulation, binding to the Hdac6 promoter
and repressing Hdac6 expression. Together, MAP3K4, CBP, HDAC6, and REL function as a
tunable program to control the phenotypic state.
A key question in both stem cell and cancer stem cell fields relates to how cells
coordinate gene expression to successfully switch as needed to different phenotypic states. Many
studies have focused on EMT-inducing TFs, however, mechanisms promoting MET are more
poorly defined. Even less clear are the gene expression programs that allow rapid switching
between different phenotypic states, giving advantages to stem cells during rapid development or
to cancer cells during disease progression. Using epithelial TSWT cells and TSKI4 cells uniquely
trapped in an intermediate state, we discovered an epigenetically regulated biological program
that controls switching between phenotypic states. We identify a small network of 183 genes
whose expression is co-regulated by MAP3K4 dependent chromatin modifiers, CBP and
HDAC6. Further, we define the key role of one of these co-regulated genes, Rel, in phenotypic
switching.
We discovered that the NF-kB family member Rel shows the most significant changes in
expression and promoter histone acetylation. CBP and HDAC6 coordinate Rel transcript levels
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epigenetically by directly binding to Rel regulatory regions promoting or repressing Rel
expression, respectively. We show that the loss of MAP3K4 activity in mesenchymal-like TSKI4
cells reduces CBP binding to Rel regulatory regions and decreases Rel expression. Further,
HDAC6 represses Rel expression by decreasing histone H2BK5 and H3K27 acetylation on Rel
regulatory regions. Importantly, re-expression of Rel in mesenchymal-like TSKI4 cells induces an
epithelial state. These findings show that this switching between CBP and HDAC6 turns up or
down Rel expression, which control selection of phenotypic states. Importantly, we show a
reciprocal regulation of HDAC6, where REL physically binds the Hdac6 promoter and represses
Hdac6 expression. Our data show that Rel expression is epigenetically coordinated by MAP3K4,
CBP, and HDAC6 to control the cellular phenotype.
Our work has broad impact, being relevant to both researchers studying development and
cancer. These new studies provide mechanistic insights into the control of switching between
epithelial, intermediate, and mesenchymal states. TSKI4 cells exist in a metastable state similar to
many aggressive cancers. Cells trapped or transitioning in intermediate states of EMT have both
epithelial and mesenchymal characteristics and exhibit stem-like properties117. High plasticity
between epithelial and mesenchymal states is critical for metastasis and is being used as a tool to
predict cancer progression, drug responsiveness, and patient survival117. Importantly, small
molecule inhibitors for CBP, HDAC6 and REL are currently available, suggesting that it will be
possible to modulate the phenotypic state using small molecule drugs. These proteins may be
therapeutically tractable targets. A key question remaining relates to the potential for direct
binding of REL to promoters or enhancers of CBP and HDAC6 co-regulated TFs. Future
experiments will also focus on the mechanisms by which the other co-regulated TFs control
cellular phenotype.
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Appendix A
Supplementary Table1: One hundred eighty-two genes whose expression is co-regulated by
MAP3K4, CBP, HDAC6, and H2BK5Ac
2610008E11Rik
2810417H13Rik
4933405L10Rik
AI317395
Abi2
Actc1
Ankrd1
Anxa6
Ap1s2
Apof
Atl1
Atp10d
Atp1b1
Atp2a1
Atrnl1
B2m
B3galt2
B4galnt3
BC051142
Bcam
Best3
Btn2a2
C2cd2l
Cadm1
Ccdc122
Ccnd1
Cd160
Cd24a
Cdc42ep2
Cdkl2
Cdkn2b
Cgn
Chst8
Clip3

Col5a2
Crebl2
Crlf1
Crygn
Cstf2t
Ctf1
Cxcl10
D030018L15Rik
Dact3
Ddr1
Dhrs11
Dnajb7
Dnmt3l
Dppa1
Dsg2
Dysf
E330021D16Rik
Echdc1
Egfr
Ehbp1l1
Eid1
Ets1
Extl1
F8a
Fam43a
Fbxo25
Fmn2
Fn1
Frzb
Gli1
Gpha2
Gpr21
Gpr75
Gpx8

Grem2
Grin3b
Hdgfrp3
Hist2h2be
Hivep2
Hmx2
Hoxa1
Hrc
Hspb2
Id2
Igf1r
Il24
Il25
Il34
Itsn2
Izumo1
Katnal2
Kbtbd3
Kbtbd7
Kctd1
Klhdc8a
Krt15
Krt20
Krt75
Krt86
Laptm5
Lcn9
Lemd1
Lhx6
Lrrc10
Lrrc23
Lrrc52
Lrrtm2
Lsp1
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Lztfl1
Malat1
Mas1
Mfge8
Minpp1
Mkrn3
Msc
Mtnr1a
Muc1
Mybpc2
Mylk2
Nacc1
Napepld
Nbeal1
Neu2
Nphp1
Nuak2
Nwd1
Padi2
Parva
Patl2
Pcdhgc3
Pcolce
Pcp4l1
Peli3
Pgam2
Pim1
Pipox
Pkd2l1
Pla1a
Pla2g7
Plag1
Plcb2
Plcxd2

Plekha1
Podnl1
Pou6f1
Ppp1r3b
Rabgap1l
Ranbp6
Rel
Rfx3
Rhobtb3
Rln3
Rnf122
Rnf186
Rnu73b
Rorc
Rtn4rl2
Runx1
Runx1t1
S100a11
Scg5
Sdc4
Sertad2
Sh3d19
Sh3rf2
Slamf9
Slc18a2
Spata20
Suox
Sv2a
Syt8
Tbc1d8b
Tlx1
Tm6sf1
Tmem171
Tnni2

Trim54
Tspyl4
Vamp5
Vps13a
Vtcn1
Wfdc13
Wfdc3
Zc3h6
Zfp273
Zfp672
Zfp784
Zfp810
Zfp819

Appendix B
Supplementary Table2: Expression of inflammatory cytokines and their receptors based on
RNA seq data
Gene Name
Tnf
Tnfaip1
Tnfaip2
Tnfaip3
Tnfaip6
Tnfaip8
Tnfaip8l1
Tnfaip8l2
Tnfaip8l3
Tnfrsf10b
Tnfrsf11a
Tnfrsf11b
Tnfrsf12a
Tnfrsf13b
Tnfrsf13c
Tnfrsf14
Tnfrsf17
Tnfrsf18
Tnfrsf19
Tnfrsf1a
Tnfrsf1b
Tnfrsf21
Tnfrsf22
Tnfrsf23
Tnfrsf25
Tnfrsf26
Tnfrsf4
Tnfrsf8
Tnfrsf9
Tnfsf10
Tnfsf11
Tnfsf12

TSWT
0.503473
9.31188
3.99433
0.247428
0.0402141
0.555961
3.4831
1.01127
0
15.2669
0.0919178
0
23.529
0
0.0170466
0
0.0421877
0
0.0215928
13.8275
1.07165
23.5352
0.970258
0.763681
0.0302003
0.0106846
0.151134
0.0397606
0.0505261
0.352579
0.0768851
0.272341

TSCBPsh
0.201222
20.5854
1.94216
0.387949
0
0.365631
3.19544
0.852431
0
18.565
0.159804
0
27.8089
0.0581457
0.179863
0.0142402
0
0.0216406
0.0966555
10.2658
2.39707
21.1015
1.22004
1.34435
0.0434522
0.00512434
0.144968
0
0.0484647
0.281829
0.22862
1.0558

TSKI4
0.0325375
17.9973
6.11774
0.680819
0.0155933
0.734512
2.65636
1.04567
0.0299601
18.1337
0.599227
0
13.7476
0.13163
0.125589
0
0
0.0437409
0.45492
22.6663
9.73204
27.8962
1.98229
1.06671
0.105393
0.00828604
0.107439
0.042398
0.0440816
0.696233
0.393528
3.07125
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TSH6sh
0
19.9188
4.02585
0.87402
0
1.00926
2.96017
0.697391
0.0251195
18.4276
0.62101
0
25.2757
0.0492691
0.0831297
0
0
0.0183369
0.27495
1.01384
4.10618
37.2863
1.56394
0.705337
0.0736375
0.0086841
0.14331
0.0161581
0.0513326
0.557211
0.462425
1.71546

Supplementary Table2: Expression of inflammatory cytokines and their receptors based on RNA
seq data (Continued)
Gene Name
Tnfsf13
Tnfsf13b
Tnfsf13os
Tnfsf14
Tnfsf15
Tnfsf18
Tnfsf4
Tnfsf8
Tnfsf9
Tnfsfm13
Il10
Il10ra
Il10rb
Il11
Il11ra1
Il11ra2
Il11ra2
Il11ra2
Il12a
Il12b
Il12rb1
Il12rb2
Il13
Il13ra1
Il13ra2
Il15
Il15ra
Il16
Il17a
Il17b
Il17c
Il17d
Il17f
Il17ra
Il17rb

TSWT
0.063011
0.00500626
0.0310036
0
0.113001
0
0
0
6.12185
0.0615356
0
0
1.12864
1.17914
2.66851
3.57329
3.33507
3.57329
0
0
0.753961
0.643435
0
0.602073
0
0
0.00773347
0.0174866
0
0.0993729
0.0478206
0.225278
0.816214
1.62349
0.0378112

TSCBPsh
0.251835
0.0360151
0.0446081
0
0.0886831
0
0
0
6.24748
0.420554
0.0125879
0.0377133
1.86207
1.11464
2.02116
2.39926
2.5389
2.39926
0
0.00838339
0.665804
0.521564
0
0.737436
0
0
0.0593437
0.0104832
0
0.119148
0
0.135054
0.791069
1.74763
0.0181343

TSKI4
0.667833
0.0407654
0.168306
0
0.0557667
0
0
0
4.10806
1.2169
0
0.0533594
1.99914
1.21262
2.13208
2.62745
2.59666
2.62745
0
0
1.0302
0.657124
0
0.811715
0
0.0139751
0.107953
0.0203416
0
0.134864
0
0.24022
0.778043
1.63305
0.0684206
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TSH6sh
0.392636
0.0162757
0.0503975
0
0.083494
0
0
0
4.29406
0.725206
0
0.0479339
1.30627
1.19449
2.63766
3.82932
4.00143
3.82932
0
0
1.02133
0.817592
0
1.46804
0
0.0146465
0.0377131
0.0106594
0
0
0
0.137324
0.8016
1.60988
0.0512196

Supplementary Table2: Expression of inflammatory cytokines and their receptors based on RNA
seq data (Continued)
Gene Name
Il17rc
Il17rd
Il17re
Il18
Il18bp
Il18r1
Il18rap
Il19
Il1a
Il1b
Il1bos
Il1f10
Il1f5
Il1f6
Il1f8
Il1f9
Il1r1
Il1r2
Il1rap
Il1rapl1
Il1rapl2
Il1rl1
Il1rl2
Il1rn
Il2
Il20
Il20ra
Il20rb
Il21
Il21r
Il22
Il22ra1
Il22ra2
Il23a
Il23r

TSWT
2.08538
1.54347
0.39258
0
0.515745
0.135619
0
0
0.191597
0
0.0230758
0
0
0
0
0.54245
0.0108072
0.342389
0.296614
0
0
0.0299243
0
0
0.931708
0
0
0.392388
0
0
0
0.0133838
0
4.25044
0

TSCBPsh
3.49435
1.25782
0.517073
0
0.494704
0.0924296
0.0219803
0.0143517
0.15872
0
0.0055336
0
0.0110105
0
0
1.08066
0.176226
0.622269
0.429672
0
0
0.0191356
0.00484149
0.0268132
1.03784
0
0
0.262681
0.0062712
0.0297656
0
0.102702
0
4.30757
0

TSKI4
2.19126
5.43345
0.322627
0
0.495197
0.116245
0
0.116033
0.0270157
0
0.00894781
0
0
0
0
0.881804
0.557343
0.663817
0.796883
0
0
0.0309422
0.00782868
0.0192697
2.13269
0.0112413
0
0.310642
0
0.0481308
0
0.0622759
0
1.47155
0
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TSH6sh
0.680065
4.13062
0.519096
0
0.359299
0.127631
0.00413884
0
0.0424703
0
0.00937766
0
0
0
0
0.66133
0.241553
0.20505
0.905275
0
0
0.0202679
0
0.0100977
1.68552
0
0
0.372074
0.00531383
0.00840717
0
0.0435118
0
1.52168
0

Supplementary Table2: Expression of inflammatory cytokines and their receptors based on RNA
seq data (Continued)
Gene Name
Il24
Il25
Il27
Il27ra
Il2ra
Il2rb
Il2rg
Il3
Il31
Il31ra
Il33
Il34
Il3ra
Il4
Il4i1
Il4ra
Il5
Il5ra
Il6
Il6ra
Il6st
Il7
Il7r
Il9
Il9r
Ildr1
Ildr2
Ilf2
Ilf3
Ilk

TSWT
1.51325
1.48648
0.437786
0.0388216
0.0301024
0.654327
3.24096
0
0
0
0.0119137
0.175513
1.40591
0.224176
1.73601
0.297887
0
0.125029
0
0.648511
2.79116
0
0
0
0.0556022
8.77183
0
12.6472
30.3256
20.512

TSCBPsh
0.45211
0.464947
0.403774
0.0744755
0.0461989
1.2375
2.14848
0
0
0
0.00571383
0.109429
1.85721
0.201591
1.85514
1.06601
0
0.341334
0
2.2745
2.64609
0.00291139
0.0257016
0
0.0333336
1.25902
0
13.2171
26.9551
21.2256

TSKI4
0.134669
0.375909
0.156696
0.0501778
0.0443552
0.105317
1.20085
0
0.0110366
0
0.0184785
0.0204169
4.11253
0.325972
2.01617
2.27683
0
2.05484
0
1.01049
2.98741
0.00235386
0.0166237
0
0.0269501
6.83991
0.0210058
11.581
31.2301
16.8013
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TSH6sh
0.403253
0.998051
0.273707
0.031553
0.0440394
0.200685
1.06537
0
0
0
0.0193662
0.0570606
3.48817
0.273305
1.6507
1.97881
0
1.24289
0
1.2676
2.8376
0
0.00871117
0.052137
0.0282448
3.34357
0.0270953
12.735
29.2093
21.0813

Appendix C
Antibodies
Antibody

Vendor

Donkey anti-mouse
peroxidase conjugate

Jackson
ImmunoResearch
Labs
Jackson
ImmunoResearch
Labs
Thermo Fisher
Scientific

Donkey anti-rabbit
peroxidase conjugate
Goat anti-mouse
polyclonal Daylight 488

Catalog
Application
Number
715-035-151 Western blotting
711-035-152 Western blotting
35503

Immunofluorescence

Mouse monoclonal antiE-cadherin

BD Biosciences

610181

Immunofluorescence

Mouse monoclonal antiGAPDH

Thermo Fisher
Scientific

AM4300

Western blotting

Mouse monoclonal antiTubulin

Sigma-Aldrich

T6793

Western blotting

Rabbit monoclonal antiCBP
Rabbit monoclonal antiCBP
Rabbit polyclonal anti-cRel

Cell Signaling
Technology
Cell Signaling
Technology
Cell Signaling
Technology

7425

ChIP

7389

Western blotting

4727

Western blotting

Rabbit monoclonal anti-cREL

Cell Signaling
Technology

12707

Western blotting

Rabbit polyclonal anti-cREL

Santa Cruz
Biotechnology

Sc-71

ChIP

Rabbit polyclonal antiHDAC6

Bethyl

A301-342A

ChIP

Rabbit monoclonal antiHDAC6

Cell Signaling
Technology

7612

Western blotting

39123

ChIP

Rabbit monoclonal anti- Active Motif
H2BK5Ac
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Antibodies (Continued)
Antibody

Vendor

Rabbit monoclonal antiH3K27Ac
Rabbit polyclonal antiIgG
Rabbit monoclonal antiLamin B1

Active Motif

Rabbit polyclonal antiNF-κB1 (p105/p50)
Rabbit polyclonal antiNF-κB2 (p100/p52)
Rabbit monoclonal antiRELA
Rabbit monoclonal antiRELB

Catalog
Number
39133
ab171870

Abcam
Cell Signaling
Technology

13435

Application
ChIP
ChIP
Western blotting

Cell Signaling
Technology

12540

Western blotting

Cell Signaling
Technology

4882

Western blotting

Cell Signaling
Technology
Cell Signaling
Technology

8242
4922

95

Western blotting
Western blotting

Appendix D
Primers for qPCR
Target name

Forward primer

Reverse primer

REL
Human
RELB
Human
2610008E11Rik
mouse
Actb
mouse
Cdh1
mouse
Cdh2
mouse
Cdx2
mouse
Cldn6
mouse
Crebl2
mouse
Crebbp
mouse
Ets1
mouse
Gapdh
mouse
Gli1
mouse
Hivep2
mouse
HoxA1
mouse
Id2
mouse
Krt8
mouse
Krt18
mouse
Nfkb1
mouse

GCC TCC GGT GCG TAT AAC
C
CAC TCT CGC TCG CCG TTT

TGC TGA TCG CCC TTC ACA TT

GAT TTG AGC CGT GGA ATG
GC
AGC CAT GTA CGT AGC CAT
CC
CAG GTC TCC TCA TGG CTT
TGC
AGC GCA GTC TTA CCG AAG
G
AAG CCA AGT GAA AAC CAG
GAC A
ATG GCC TCT ACT GGT CTG
CAA
TGG ATG ACA GCA AGG TGG
TT
GGC TTC TCC GCG AAT GAC
AA
CTC TCC AGA CAG ACA CCT
TGC
AGG TCG GTG TGA ACG GAT
TTG
ATC ACC TGT TGG GGA TGC
TG
GGC TCG GTG AAG TCT GTG
AG
CAG GAA GCA GAC CCA CCA
AG
ATG AAA GCC TTC AGT CCG
GTG
CGG CTA CTC AGG AGG ACT
GA
GTG GAT GCC CCC AAA TCT
CA
ATG GCA GAC GAT GAT CCC
TAC

GTT CTG CTT CAA CCA TCT
GTT CA
CTC TCA GCT GTG GTG GTG AA
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CGA AGC CGT TCT CCT TGA TG

CTT CCG AAA AGA AGG CTG
TCC
TCG CTG CTT TCA TAC TGA
ACT TT
GGC AGC CAG CTC ACT TTT C
GCC AAC AGT GAG TCA TAC
ACC TT
GAT TTT GGC TGG CTT CCG TC
GTT TGG ACG CAG CAT CTG GA
CGG CCC ACT TCC ACG ACT
TGT AGA CCA TGT AGT TGA
GGT CA
AAT CGA ACT CCT GGC TGC AA
CTG GCT GGC TGT TGA GAG AA
ACC CAC GTA GCC GTA CTC T
AGC AGA CTC ATC GGG TCG
TGA AAG TGT TGG ATC CCC CG
CCT CAA TCT GCT GAG ACC
AGT
TGT TGA CAG TGG TATT TCT
GGT G

Primers for qPCR (Continued)
Target name

Forward primer

Reverse primer

Nfkb2
mouse
Pou6f1
mouse
Rel
mouse
RelA
mouse
RelB
mouse
Rfx3
mouse
Rps11
mouse
Runx1
mouse
Snai2
mouse
Tlx1
mouse
Twist1
mouse
Vim
mouse
Zeb1
mouse
Zfp672
mouse
Zfp810
mouse

GGC CGG AAG ACC TAT CCT
ACT
CTC CAA GAT CAG TGC AGC
CTC C
ACC TCA ATG TGG TGA GGC
TG
AGG CTT CTG GGC CTT ATG
TG
CTC CAT TCC GAA GCC AAC
CT
CCT CCA GCT GTC TCA GAG
ATT T
CGC GTG GTG AAT AAG GAA
GC
GC AGG CAA CGA TGA AAA
CTA CT
TGG TCA AGA AAC ATT TCA
ACG CC
GCT TGC CTA CAG TAC CCT
CTG
GGA CAA GCT GAG CAA GAT
TCA
TCC ACA CGC ACC TAC AGT
CT
ACC GCC GTC ATT TAT CCT
GAG
TAT CCC AGG CTG CAG GTA
CA
CGA CTC CGC CAT GAT GTA
GA

CTA CAG ACA CAG CGC ACA
CT
CGT GAG GAT CTG ACT GCT GA

97

TT GGG GCA CGG TTG TCA TAA
TGC TTC TCT CGC CAG GAA
TAC
GGC TCA AAG AGA ACC GGA
GT
GTC TGA ACC CGT CTC TGA
AGT
GTA AGC ACG CTC CGT CTG AA
GCA ACT TGT GGC GGA TTT
GTA
GGT GAG GAT CTC TGG TTT
TGG TA
TAG GGG TGA CCT GTG AAC CT
CGG AGA AGG CGT AGC TGA G
CCG AGG ACC GGG TCA CAT A
CAT CTG GTG TTC CGT TTT CAT
CA
ACC TTT GGG GAG CTT CGT TT
GTC ATG CAG TGC CCA TTT CC

Appendix E
ChIP-PCR Primers for Rel promoter and distal regulatory regions where numbers indicate the
distance from Rel TSS
Target name

Forward primer

Reverse primer

-700

GAG ATT GGC CGA GAT ACC CA

GCA AAC AAG ATT CCG CCT GA

+140699

CAG AGG GAG GCT GTT AGT
CCT

CTT TCA GAA TCA GAG CCA
ACC G

+105579

CTG CGG CAT CTT GGG AGA A

TCT TCG ACA CCC AGT CCC TA

+101930

TCC CGC ACC TTA CAA ACA CC

ACA GGA CTC AAA GCT AGT
GAC A

+83091

GTT TTC TCC TTT TCC CTC CCT

TAG GAC ATA CCA GCT TTT
ACG G

+71150

CCC TCT GGC TTT GCA CCA TA

CCC CTG TCA CAC ATG CTG AA

+46498

GAA CTC GGG CCA TTC ACT CT

GGC AGA AGG ATA CGT TCC
AG

+40681

TTG TGT GGG CCG GAA TAG AT

CAC TGC AAC TCA CCC TCA CT

+35817

GTG GGA TTA CTT CAA GGA
TGG GT

TAC ATA TCT TTG ATG GGT
CTG CTA A

+33455

GTT GGT CTG AGC TGA GCA
GAT A

GAG GTT TGT GTG GTG CTA
GAG

+29050

GAT GGG CCA CTG AGG GTA TG

CCA GGG CAA GCT GAA CCT TA

-9753

TCA GGA ATA AAA GAA GGC
ACT CTA

TGA ATT TCT TAT CTA GGC
CCA CAC T

-37106

AGT CTG AGC TGT GCT TTA
CGG

TCT GTG CTG GAG TTC CCC
TAC

98

ChIP-PCR Primers for Rel promoter and distal regulatory regions where numbers indicate the
distance from Rel TSS (Continued)
Target name

Forward primer

Reverse primer

-120247

TCT CCC TGG TCT GTG GGA TT

-297506

AGT TTC CAC CGA GAC AGA CC

GCA GAA ACA AGG GGA AAT
TGA CA
CAG TGA GAG CAT CCC GTA CA
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